US20020156089A1 - Use of CRF antagonists and related compositions - Google Patents

Use of CRF antagonists and related compositions Download PDF

Info

Publication number
US20020156089A1
US20020156089A1 US10/161,816 US16181602A US2002156089A1 US 20020156089 A1 US20020156089 A1 US 20020156089A1 US 16181602 A US16181602 A US 16181602A US 2002156089 A1 US2002156089 A1 US 2002156089A1
Authority
US
United States
Prior art keywords
methyl
ethyl
phenyl
alkyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/161,816
Inventor
Yuhpyng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US10/161,816 priority Critical patent/US20020156089A1/en
Publication of US20020156089A1 publication Critical patent/US20020156089A1/en
Priority to US10/676,201 priority patent/US20040082597A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to the use of CRF antagonists in the treatment of certain conditions, and related compositions.
  • CRF antagonists are disclosed in U.S. Pat. Nos. 4,605,642 (Issued Aug. 12, 1986) and 5,063,245 (issued Nov. 5, 1991). They are also disclosed in International patent publications WO 95/33750 (published Dec. 14, 1995); WO 95/34563 (published Dec. 21, 1995); WO 94/13676 (published Jun. 23, 1994); WO 94/13677 (published Jun. 23, 1994); WO 95/33727 (published Dec. 14, 1995); WO 98/05661 (published Feb. 12, 1998); WO 98/08847 (published Mar. 5, 1998); and WO 98/08846 (published Mar. 5, 1998) and European patent publications EP 778277 (published Jun.
  • CRF antagonists are also disclosed in the following patent publications: EP 576350; WO 95/10506 (published Apr. 20, 1995); WO 96/35689 (published Nov. 14, 1996); WO 96/39400 (published Dec.12, 1996); WO 97/00868 (published Jan. 9, 1997); WO 97/14684 (published Apr. 24, 1997); WO 97/29109 (published Aug. 14, 1997); WO 97/29110 (published Aug. 14, 1997); WO 97/35580 (published Oct. 2, 1997); WO 97/35846 (published Oct. 2, 1997); WO 97/44038 (published Nov. 27, 1997); WO 98/03510 (published Jan.
  • CRF antagonists are set out in the literature, e.g., P. Black, Scientific American SCIENCE & MEDICINE,1995, p. 16-25; T. Lovenberg, et al., Current Pharmaceutical Design, 1995, 1: 305-316; and U.S. Pat. No. 5,063,245.
  • An outline of the activities possessed by CRF antagonists is found in M. J. Owens et al., 1991, Pharm. Rev., 43:425-473.
  • CRF antagonists are described in the art as being effective in the treatment of stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthemia, bipolar disorders, and cyclothymia; chronic fatigue syndrome; eating disorders such as anorexia and bulimia nervosa; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; pain perception such as fibromyalgia; headache; gastrointestinal diseases; hemorrhagic stress; ulcers; stress-induced psychotic episodes; fever; diarrhea; post-operative ileus; colonic hypersensitivity; irritable bowel syndrome; Crohn's disease; spastic colon; inflammatory disorders such as rheumatoid arthritis and osteoarthritis; pain; asthma; psoriasis; allergies; osteoporosis; premature birth; hypertension, congestive heart failure; sleep disorders; neurodegenerative diseases such as
  • the present invention relates to a method of treating a condition comprising administering a corticotropin releasing factor (CRF) antagonist in an amount effective to treat the condition, the condition being selected from the group consisting of:
  • the present invention relates to a method for treating or preventing a cardiovascular disease that involves administering a CRF antagonist in combination with a non-CRF antagonist compound for treating the disease.
  • the invention also relates to treatment of migraine or non-migraine headache by administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition and to treatment of emesis using a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis.
  • the present invention provides for treatment of disorders that can be treated by altering circadian rhythm, e.g., abnormal circadian rhythm, by administration of a CRF antagonist.
  • Abnormal circadian rhythm treated according to the invention can be associated with several types of disorders, including, without limitation, time zone change syndrome, seasonal affective disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24 hour sleep wake disorder, light-induced clock resetting, REM sleep disorder, hypersomnia, parasomnia, narcolepsy, nocturnal enuresis, restless legs syndrome, sleep apnea, dysthymia, and abnormal circadian rhythm associated with chronic administration and withdrawal of antidepressant agents.
  • a second compound e.g., a non-CRF antagonist that is useful for treating sleep disorder
  • a second compound useful for treating sleep disorder may be employed, including but not limited to tachykinin antagonists, melatoninergic agonists, such as melatonin, GABA brain receptor agonists, serotonin receptor (such as 5HT1b, 5HT2c, 5HT7) antagonists, inverse agonists, agonists and other compounds.
  • Specific compounds for treatment of sleep disorder include melatonin, carpipramine, and doxylamine. These and other compounds are described, for example, in U.S. Pat. Nos. 5,908,932; 5,902,813; 5,883,094; 5,874,450; 5,849,781; 5,856,529; and 4,956,362.
  • the invention also encompasses treatment of depression with a CRF antagonist and with a second compound having delayed action for treating depression.
  • the CRF antagonist initiates treatment of the depression with a quick-acting effect, which treatment is supplemented by the delayed effect of the second compound.
  • Compounds for treating depression that have a delayed effect include, without limitation, compounds that are selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, norepinephrine reuptake inhibitors, noradrenaline reuptake inhibitors, lithium, ⁇ 2-adrenoreceptor agonists, 5HT 1A inhibitors, and monoamine oxidase type A inhibitors.
  • SSRIs selective serotonin reuptake inhibitors
  • tricyclic antidepressants include, without limitation, compounds that are selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, norepinephrine reuptake inhibitors, noradrenaline reuptake inhibitors, lithium, ⁇ 2-adrenoreceptor agonists, 5HT 1A inhibitors, and monoamine oxidase type A inhibitors.
  • Examples include bupropion, sertraline, fluoxetine, trazodone, citalopram, fluvoxamine, paroxetine, venlafaxine, roboxetine, imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, brofaromine, milnacipran, and buspirone. It understood by those skilled in this art that compounds administered for treatment of depression may have other beneficial effects, such as ameliorating sleep disturbance or sexual dysfunction.
  • Compounds having a delayed effect for treating depression also include the combination of an SSRI and 5HT 2 antagonist (such as risperidone) administered, for example, to patients who do not respond to SSRI therapy alone. Administration of these delayed-action compounds for treating depression is carried out using well-known dosages and formulations.
  • an SSRI and 5HT 2 antagonist such as risperidone
  • Any CRF antagonist can be used to practice the invention, including those that are described in U.S. Pat. Nos. 4,605,642 and 5,063,245; International patent publications WO 95/33750; WO 95/34563; WO 94/13676; W094/13677; WO 95/33727; WO 98/05661; WO 98/08847; and WO 98/08846; and European patent publications EP 778277; and EP 773023.
  • the CRF antagonist may be of the following formula, described in WO 94/13677:
  • A is NR 1 R 2 , CR 1 R 2 R 11 , or C( ⁇ CR 1 R 12 )R 2 , NHCR 1 R 2 R 11 , OCR 1 R 2 R 11 , SCR 1 R 2 R 11 , NHNR 1 R 2 , CR 2 R 11 NHR 1 , CR 2 R 11 OR 1 , CR 2 R 11 SR 1 or C(O)R 2 ;
  • R 1 is hydrogen, or C 1 -C 6 alkyl which may be substituted by one or two substituents R 6 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C 1 -C 6 alkoxy, O—C(O)-(C 1 -C 6 alkyl), O—C(O)—N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl); amino, NH(C 1 -C 4 alkyl, S(C 1 -C 6 alkyl), OC(O)NH(C 1 -C 4 alkyl), N(C 1 -C 2 alkyl)C(O)(C 1 -C 4 alkyl), NHC(O)(C 1 -C 4 alkyl), COOH, CO(C 1 -C 4 alkyl), C(O)NH(C 1 -C 4 alkyl), C(O)N(C 1 -C 4 alkyl)(C
  • R 2 is C 1 -C 12 alkyl, aryl or (C 1 -C 10 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, or benzoxazolyi; 3- to 8-membered cycloalkyl or (C 1 -C 6 alkylene) cycloalkyl, wherein said cycloalkyl may have one or two of O
  • NR 1 R 2 or CR 1 R 2 R 11 may form a 4- to 8-membered ring optionally having one or two double bonds or one or two of O, S or N—Z wherein Z is hydrogen, C 1 -C 4 alkyl, benzyl, or C 1 -C 4 alkanoyl;
  • R 3 is hydrogen, C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C 1 -C 6 alkyl), NH(C 1 -C6 alkyl), N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), SH, S(C 1 -C 4 alkyl), SO(C 1 -C 4 alkyl), or SO 2 (C 1 -C 4 alkyl), wherein said C 1 -C 4 alkyl and C 1 -C 6 alkyl may have one or two double or triple bonds and may be substituted by from 1 to 3 R 7 substituents independently selected from the group consisting of hydroxy, amino, C 1 -C 3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHC(O)CH 3 , fluoro, chloro or C 1 -C 3 thioalkyl;
  • R 4 is hydrogen, C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, C 1 -C 6 alkoxy, amino, NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) (C 1 -C 2 alkyl), SO n (C 1 -C 6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C 1 -C 6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(O)(C 1 -C 4 alkyl), NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), C(O)O(C 1 -C 4 alkyl), C 1 -C 3 alkoxy, C 1 -C 3 thioalkyl, fluoro, bromo, chloro
  • R 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, piperazinyl, piperidinyl, or tetrazolyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C 1 -C 6 alkyl, C
  • R 11 is hydrogen, hydroxy, fluoro, chloro, COO(C 1 -C 2 alkyl), cyano, or CO(C 1 -C 2 alkyl);
  • R 12 is hydrogen or C 1 -C 4 alkyl
  • A is not straight chain C 1 -C 12 alkyl
  • R 3 when R 3 is hydrogen, A is benzyl or phenethyl, and R 4 is fluoro, chloro, bromo or iodo, then R 5 is not 5′-deoxy-ribofuranosyl or 5′-amino-5′-deoxy-ribofuranosyl; and
  • the invention also relates to use of a CRF antagonist of the following formula, described in WO 94113676:
  • B is XA wherein X is (CH 2 ) n in which n is 0, 1 or 2, NH, O, S, N(C 1 -C 4 alkyl);
  • A is NR 1 R 2 , CR 1 R 2 R 11 , or C( ⁇ CR 2 R 12 )R 1 ;
  • R 2 is C 1 -C 12 alkyl, aryl or (C 1 -C 10 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3- 8 -membered cycloalkyl or (C 1 -C 6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of
  • R 1 and R 2 taken together with the atom to which they are attached may form a saturated 4- to 8-membered optionally containing one or two double bonds or one or two of O, S or N—Z wherein Z is hydrogen, C 1 -C 4 alkyl, or C 1 -C 4 alkanoyl;
  • R 3 is hydrogen, C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C 1 -C 6 alkyl), NH(C 1 -C 6 alkyl), N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), SH, S(C 1 -C 4 alkyl), SO(C 1 -C 4 alkyl), or SO 2 (C 1 -C 4 alkyl), wherein said C 1 -C 4 alkyl and C 1 -C 6 alkyl may contain from one or two double or triple bonds and may be substituted by from 1 to 3 substituents R 8 independently selected from the group consisting of hydroxy, amino, C 1 -C 3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHCH 3 , fluoro, chloro or C 1 -C 3 thioalkyl;
  • R 4 and R 6 are each independently hydrogen, C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, C 1 -C 6 alkoxy, amino, NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl)(C 1 -C 2 alkyl), SO n (C 1 -C6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C 1 -C 6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC( ⁇ O)(C 1 -C 4 alkyl), NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), C( ⁇ O)O(C 1 -C 4 alkyl), C 1 -C 3 alkoxy, C 1 -C 3 thioalkyl, fluoro
  • R 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N
  • R 11 is hydrogen, hydroxy, fluoro, chloro, COO(C 1 -C 2 alkyl), cyano, or CO(C 1 -C 2 alkyl);
  • R 12 is hydrogen or C 1 -C 4 alkyl; with the proviso that (1) when R 5 is 4-bromophenyl, R 3 is hydrogen, and R 4 and R 6 are methyl, then B is not methylamino or ethyl, and (2) when R 5 is 4-bromophenyl, and R 3 , R 4 and R 6 are methyl, then B is not 2-hydroxyethylamino.
  • CRF antagonist that has a structure selected from the group shown below, and pharmaceutically acceptable salts and esters thereof, as described in WO 95/33750:
  • A is CR 7 or N
  • B is NR 1 R 2 , CR 1 R 2 R 11 , C( ⁇ CR 2 R 12 )R 1 , NHCHR 1 R 2 , OCHR 1 R 2 , SCHR 1 R 2 , CHR 2 OR 12 , CHR 2 SR 12 , C(S)R 2 or C(O)R 2 ;
  • Y is CH or N
  • Z is NH, O, S, N (C 1 -C 2 alkyl), or CR 13 R 14 , wherein R 13 and R 14 are each independently hydrogen, trifluoromethyl, or C 1 -C 4 alkyl, or one of R 13 and R 14 may be cyano, chloro, bromo, iodo, fluoro, hydroxy, O(C 1 -C 2 alkyl), amino, NH(C 1 -C 2 alkyl), or CR 13 R 14 may be C ⁇ O or cyclopropyl;
  • R 1 is C 1 -C 6 alkyl which may be substituted by one or two substituents R 8 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, O—CO-(C 1 -C 4 alkyl), O—CO—NH(C 1 -C 4 alkyl), O—CO—N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), NH(C 1 -C 4 alkyl), N(C 1 -C 2 alkyl)(C 1 -C 4 alkyl), S(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)CO(C 1 -C 4 alkyl), NHCO(C 1 -C 4 alkyl), COO(C 1 -C 4 alkyl), CONH(C 1 -C 4 alkyl), CON(C 1 -C 4 alkyl)(C 1 -
  • R 2 is C 1 -C 12 alkyl, aryl or (C 1 -C 4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C 1 -C 6 alkylene)cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N—R 9 wherein R 9 is hydrogen, or C 1 -C 4 alkyl, wherein the above defined R 2 may be substituted independently by from one to three of chloro, fluor fluor
  • NR 1 R 2 or CR 1 R 2 R 11 may form a saturated 5- to 8-membered carbocyclic ring which may contain one or two double bonds or one or two of O or S;
  • R 3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF 3 , methylthio, methylsulfonyl, CH 2 OH or CH 2 OCH 3 ;
  • R 4 is hydrogen, C 1 -C 4 alkyl, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, amino, nitro, NH(C 1 -C 4 alkyl), N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), SO n (C 1 -C 4 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, CO(C 1 -C 4 alkyl), CHO, or COO(C 1 -C 4 alkyl), wherein said C 1 -C 4 alkyl may contain one or two double or triple bonds and may be substituted by one or two of hydroxy, amino, carboxy, NHCOCH 3 , NH(C 1 -C 2 alkyl), N(C 1 -C 2 alkyl) 2 , COO(C 1 -C 4 alkyl), CO(C 1 -C 4 alkyl), C 1 -C 3 alkoxy,
  • R 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each one of the above groups R 5 is substituted independently by from one to three of fluoro, chloro, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy, or one of hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, NH(C 1 -C 4 alkyl), N(C 1 -C 6 )(C 1 -C 2 alkyl), COOH, COO(C 1 -C 4 alkyl), CO(C 1 -C 4 alkyl), SO 2 NH(C 1 -C 4 alkyl), SO 2 N(C 1 -C 4 alkyl)
  • R 6 is hydrogen, or C 1 -C 6 alkyl, wherein said C 1 -C 6 alkyl may be substituted by one hydroxy, methoxy, ethoxy or fluoro;
  • R 7 is hydrogen, C 1 -C 4 alkyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, O(C 1 -C 4 alkyl), C(O)(C 1 -C 4 alkyl), or C(O)O(C 1 -C 4 alkyl), wherein the C 1 -C 4 alkyl groups may be substituted with one hydroxy, chloro or bromo, or one to three fluoro;
  • R 11 is hydrogen, hydroxy, fluoro, or methoxy
  • R 12 is hydrogen or C 1 -C 4 alkyl
  • R 16 and R 17 are each independently hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that they are not both methoxy or ethoxy, and CR 4 R b 6 and CR 16 R 17 each independently may be C ⁇ O.
  • A is N or —CR 6 ;
  • B is —NR 1 R 2 , —CR 1 R 2 R 11 , —C( ⁇ CR 2 R 12 )R 1 , —NHCHR 1 R 2 , —OCHR 1 R 2 , —SCHR 1 R 2 , —CHR 2 OR 12 , —CHR 2 SR 12 , —C(S)R 1 or —C(O)R 1 ;
  • R 1 is C 1 -C 6 alkyl which may optionally be substituted with one or two substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, —O—CO-(C 1 -C 4 alkyl), —O—CO—NH(C 1 -C 4 alkyl), —O—CO—N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —NH(C 1 -C 4 alkyl), —N(C 1 -C 2 alkyl)(C 1 -C 4 alkyl), —S(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)CO(C 1 -C 4 alkyl), —NHCO(C 1 -C 4 alkyl), —COO(C 1 -C 4 alkyl), —CONH(C 1 -C 4 alkyl
  • R 2 is C 1 -C 12 alkyl, aryl, -(C 1 -C 4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8-membered cycloalkyl or -(C 1 -C 6 alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at
  • —NR 1 R 2 may form a saturated 5- to 8-membered heterocyclic ring, or —CHR 1 R 2 may form a saturated 5- to 8-membered carbocyclic ring, wherein each of these rings may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;
  • R 3 is C 1 -C 4 alkyl, fluoro, chloro, bromo, iodo, —CH 2 OH, —CH 2 OCH 3 , —O(C 1 -C 3 alkyl), —S(C 1 -C 3 alkyl), or —SO 2 (C 1 -C 3 alkyl), wherein said C 1 -C 3 alkyl may optionally contain one carbon-carbon double or triple bond;
  • R 4 is hydrogen, C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, amino, —NHCH 3 , —N(CH 3 ) 2 , —CH 2 OH, —CH 2 OCH 3 , or —SO n (C 1 -C 4 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, —CO(C 1 -C 4 alkyl), —CHO, or —COO(C 1 -C 4 alkyl) wherein the C 1 -C 4 alkyl moieties in the foregoing R 4 groups may optionally contain one carbon-carbon double or triple bond;
  • R 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R 5 may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C 1 -C 6 alkyl and C 1 -C 6 alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, —NH(C 1 -C 4 alkyl), —N(C 1 -C 6 )(C 1 -C 2 alkyl), —COO(C 1 -C 4 alkyl), —CO(C 1 -C 4 alkyl), —COOH, —SO 2 NH(C 1 -C 4 alkyl), —SO 2 N(C 1 -C 4 al
  • R 6 is hydrogen, C 1 -C 4 alkyl, fluoro, chloro, bromo, iodo, —CH 2 OH, —CH 2 OCH 3 , or C 1 -C 4 alkoxy;
  • R 7 is hydrogen, C 1 -C 4 alkyl, fluoro, chloro, bromo, iodo, —O(C 1 -C 4 alkyl), cyano, —CH 2 OH, —CH 2 O(C 1 -C 2 alkyl), —CO(C 1 -C 2 alkyl), or —COO(C 1 -C 2 alkyl);
  • R 11 is hydrogen, hydroxy, fluoro, or methoxy
  • R 12 is hydrogen or C 1 -C 4 alkyl
  • the CRF antagonist is of the following formula, disclosed in EP 778277:
  • A is nitrogen or CR 7 ;
  • B is —NR 1 R 2, —CR 1 R 2 R 10 , —C( ⁇ CR 2 R 11 )R 1 , —NHCR 1 R 2 R 10 , —OCR 1 R 2 R 10 , —SCR 1 R 2 R 10 , —CR 2 R 10 NHR 1 , —CR 2 R 10 OR 1 , —CR 2 R 10 SR 1 or —COR 2 ;
  • D is nitrogen and is single bonded to all atoms to which it is attached, or D is carbon and is either double bonded to E in formulas I and II or double bonded to the adjacent carbon atom common to both fused rings in formula III, or D is CH and is single bonded to E in formulas I and II;
  • E is nitrogen, CH or carbon
  • F is oxygen, sulfur, CHR 4 or NR 4 when it is single bonded to E and F is nitrogen or CR 4 when it is double bonded to E;
  • G when single bonded to E, is hydrogen, C 1 -C 4 alkyl, —S(C 1 -C 4 alkyl), —O(C 1 -C 4 alkyl), NH 2 , —NH(C 1 -C 4 alkyl) or —N(C 1 -C 2 alkyl)(C 1 -C 4 alkyl), wherein each of the C 1 -C 4 alkyl groups of G may optionally be substituted with one hydroxy, —O(C 1 -C 2 alkyl) or fluoro group; G, when double bonded to E, is oxygen, sulfur or NH; and G, when E is nitrogen and double bonded to D or F, is absent;
  • R 1 is hydrogen, C 1 -C6 alkyl optionally substituted with one or two substituents R 8 independently selected from hydroxy, fluoro, chloro, bromo, iodo, C 1 -C4 alkoxy, CF 3 , —C( ⁇ O)O-(C 1 -C 4 )alkyl, —OC( ⁇ O)(C 1 -C4 alkyl), —OC( ⁇ O)N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —NHCO(C 1 -C 4 alkyl), —COOH, —COO(C 1 -C4 alkyl), —CONH(C 1 -C 4 alkyl), —CON(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —CN, —NO 2 , —SO(C 1 -C 4 alkyl), —SO
  • R 2 is C 1 -C 12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C 1 -C 4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C 3 -C 8 cycloalkyl or (C 3 -C 6 alkylene)(C 3 -C 8 cycloalkyl), wherein one or two of the carbon atoms of said cycloal
  • —NR 1 R 2 or CR 1 R 2 R 10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 3 wherein Z 3 is hydrogen, C 1 -C4 alkyl, benzyl or C 1 -C 4 alkanoyl;
  • R 3 is hydrogen, C 1 -C 4 alkyl, —O(C 1 -C 4 alkyl), chloro, fluoro, bromo, iodo, —CN, —S(C 1 -C 4 alkyl) or —SO 2 (C 1 -C 4 alkyl) wherein each of the (C 1 -C 4 alkyl) moieties in the foregoing R 3 groups may optionally be substituted with one substituent R 9 selected from hydroxy, fluoro and (C 1 -C2 alkoxy);
  • each R 4 is, independently, hydrogen, (C 1 -C 6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, nitro, —O(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —SO(C 1 -C 4 alkyl), —SO 2 (C 1 -C 4 )alkyl, —CO(C 1 -C 4 alkyl), —C( ⁇ O)H or —C( ⁇ O)O(C 1 -C 4 alkyl), wherein each of the (C 1 -C 6 alkyl) and (C 1 -C 4 alkyl) moieties in the foregoing R 4 groups may optionally contain one or two double or triple bonds and may optionally be substituted with one or two substituents independently selected from hydroxy, amino, C 1 -
  • R 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl or C 3 -C 8 cycloalkyl wherein one or two of the carbon atoms of said cycloalkyl rings that contain at least 5 ring members may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 4 wherein Z 4 is hydrogen, C 1 -C 4 alkyl or benzyl; and wherein each of the foregoing R 5 groups is substituted with from one to four substituents R 12 wherein one to three of said substituents may be selected, independently, from chloro, C 1 -C 6 alkyl and —O(C 1 -C 6 alkyl
  • R 7 is hydrogen, C 1 -C 4 alkyl, halo, cyano, hydroxy, —O(C 1 -C 4 alkyl) —C( ⁇ O)(C 1 -C 4 alkyl), —C( ⁇ O)O(C 1 -C 4 alkyl), —OCF 3 , —CF 3 , —CH 2 OH, —CH 2 O(C 1 -C 4 alkyl);
  • R 10 is hydrogen, hydroxy, methoxy or fluoro
  • R 11 is hydrogen or C 1 -C 4 alkyl
  • Z is NH, oxygen, sulfur, —N(C 1 -C 4 alkyl), —NC( ⁇ O)(C 1 -C 2 alkyl), NC( ⁇ O)O(C 1 -C 2 alkyl) or CR 13 R 14 wherein R 13 and R 14 are independently selected from hydrogen, trifluoromethyl and methyl with the exception that one of R 13 and R 14 can be cyano;
  • the CRF antagonist can also be of the following formula, disclosed in WO 98/05661:
  • A is nitrogen or CR 7 ;
  • B is —NR 1 R 2 , —CR 1 R 2 R 10 , —C( ⁇ CR 2 R 11 )R 1 , —NHCR 1 R 2 R 10 , —OCR 1 R 2 R 10 , —SCR 1 R 2 R 10 , —CR 2 R 10 NHR 1 , —CR 2 R 10 OR 1 , —CR 2 R 10 SR 1 or —COR 2 , and is single bonded to D; or B is —CR 1 R 2 , and is double bonded to D and D is carbon;
  • D is nitrogen or CR 4 and is single bonded to all atoms to which it is attached, or D is carbon and is double bonded to E or double bonded to B;
  • E is oxygen, nitrogen, sulfur, C ⁇ O, C ⁇ S, CR 6 R 12 , NR 6 or CR 6 ; or E is a two atom spacer, wherein one of the atoms is oxygen, nitrogen, sulfur, C ⁇ O, C ⁇ S, CR 6 R 12 , NR 6 or CR 6 , and the other is CR 6 R 12 or CR 9 ;
  • K and G are each, independently, C ⁇ O, C ⁇ S, sulfur, oxygen, CHR 6 or NR 8 when single bonded to both adjacent ring atoms, or nitrogen or CR 8 when it is double bonded to an adjacent ring atom;
  • the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C ⁇ O or C ⁇ S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring;
  • R 1 is C 1 -C 6 alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, CF 3 , —C( ⁇ O)(C 1 -C 4 alkyl), —C( ⁇ O)—O-(C 1 -C 4 )alkyl, —OC( ⁇ O)(C 1 -C 4 alkyl), —OC( ⁇ O)N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —NHCO(C 1 -C 4 alkyl), —COOH, —COO(C 1 -C 4 alkyl), —CONH(C 1 -C 4 alkyl), —CON(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —CN, —NO 2 ,
  • R 2 is C 1 -C 12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C 1 -C 4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C 1 -C 4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C 3 -C 8 cycloalkyl or (C 1 -C 6 alkylene)(C 3 -C 8 cycloalkyl), wherein one or two of the carbon atoms of said cyclo
  • —NR 1 R 2 or CR 1 R 2 R 10 may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 3 wherein Z 3 is hydrogen or C 1 -C 4 alkyl;
  • R 3 is hydrogen, C 1 -C 4 alkyl, —O(C 1 -C 4 alkyl), chloro, fluoro, bromo, iodo, —S(C 1 -C 4 alkyl) or —SO 2 (C 1 -C 4 alkyl);
  • R 4 is hydrogen, C 1 -C 2 alkyl, hydroxy or fluoro
  • each R 6 , R 8 and R 9 that is attached to a carbon atom is selected, independently, from hydrogen, C 1 -C 2 alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxymethyl, formyl, trifluoromethyl, cyano, amino, nitro, —O(C 1 -C 2 alkyl), —N(C 1 -C 2 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 2 alkyl), —CO(C 1 -C 2 alkyl), —C( ⁇ O)H or —C( ⁇ O)O(C 1 -C 2 alkyl), wherein each of the C 1 -C 2 alkyl moieties in the foregoing R 6 , R 8 , and R 9 groups may optionally contain one double or triple bond; and each R 6 , R 8 , and R 9 that is attached to a nitrogen atom is selected, independently, from hydrogen and C 1
  • R 5 is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R 5 groups is substituted with from two to four substituents R 15 , wherein from one to three of said substituents may be selected, independently, from chloro, C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl) and -(C 1 -C 6 alkylene)O(C 1 -C 6 alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, —NH(C 1 -C 4 alkyl), —N(C 1 -C 2 alkyl)(C 1 -C 6 alkyl), —C( ⁇ O)O(C 1 -C4 alkyl), —C( ⁇ O)(C 1 -C 4 alkyl), —CO
  • R 7 is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, —C( ⁇ O)(C 1 -C 2 alkyl), —C( ⁇ O)O(C 1 -C 2 alkyl), trifluoromethoxy, hydroxymethyl, trifluoromethyl or formyl;
  • halo e.g., chloro, fluoro, iodo or bromo
  • R 10 is hydrogen, hydroxy, methoxy or fluoro
  • R 11 is hydrogen or C 1 -C 4 alkyl
  • R 12 is, hydrogen or methyl
  • Z is NH, oxygen, sulfur, —N(C 1 -C 4 alkyl), or CR 13 R 14 wherein R 13 and R 14 are independently selected from hydrogen, and methyl with the exception that one of R 13 and R 14 may optionally be cyano;
  • the CRF antagonist can also be of the following formula, disclosed in WO 98/08847:
  • A is nitrogen or CR 7 ;
  • B is —NR 1 R 2 , —CR 1 R 2 R 10 —C( ⁇ CR 2 R 11 )R 1 , —NHCR 1 R 2 R 10 , —OCR 1 R 2 R 10 , —SCR 1 R 2 R 10 , —CR 2 R 10 NHR 1 , —CR 2 R 10 OR 1 , —CR 2 R 10 SR 1 or —COR 2 ;
  • J and K are each independently nitrogen or carbon and both J and K are not nitrogens;
  • D and E are each selected, independently, from nitrogen, CR 4 , C ⁇ O, C ⁇ S, sulfur, oxygen, CR 4 R 6 and NR 8 ;
  • G is nitrogen or carbon
  • the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C ⁇ O or C ⁇ S groups;
  • R 1 is C 1 -C 6 alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, —O-(C 1 -C 4 alkyl), CF 3 , —C( ⁇ O)O-(C 1 -C 4 alkyl), —OC( ⁇ O)(C 1 -C 4 alkyl), —OC( ⁇ O)N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —NHCO(C 1 -C 4 alkyl), —COOH, —COO(C 1 -C 4 alkyl), —CONH(C 1 -C 4 alkyl), —CON(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —CN, —NO 2 , —SO(C 1 -C 4 alkyl), —SO 2
  • R 2 is C 1 -C 12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C 1 -C 4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C 1 -C 4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C 3 -C 8 cycloalkyl or (C 1 -C 6 alkylene)(C 3 -C 8 cycloalkyl), wherein one or two of the carbon atoms of said cyclo
  • —NR 1 R 2 or CR 1 R 2 R 10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 3 wherein Z 3 is hydrogen, C 1 -C 4 alkyl, benzyl or C 1 -C 4 alkanoyl;
  • R 3 is hydrogen, C 1 -C 4 alkyl, —O(C 1 -C 4 alkyl), chloro, fluoro, bromo, iodo, (C 1 -C 2 alkylene)-O-(C 1 -C 2 alkyl), (C 1 -C 2 alkylene)-OH, or —S(C 1 -C 4 alkyl);
  • each R 4 is, independently, hydrogen, (C 1 -C 6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C 1 -C 2 alkylene)-OH, CF 3 , CH 2 SCH 3 , nitro, —O(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —CO(C 1 -C 4 alkyl), —C( ⁇ O)H or —C( ⁇ O)O(C 1 -C 4 alkyl);
  • R 6 is hydrogen, methyl or ethyl
  • R 8 is hydrogen or C 1 -C 4 alkyl
  • R 5 is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R 5 groups is substituted with from one to four substituents R 13 wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C 1 -C 6 alkyl and —O(C 1 -C 6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C 1 -C 4 alkylene)-OH, (C 1 -C 4 alkylene)-O-(C 1 -C 2 alkyl), —CN, —CF 3 , —NO 2 , —NH 2 , —NH(C 1 -C 4 alkyl), —N(C 1 -C 2 alkyl)(C 1 -C 6 alkyl), —OCO(C 1 -C 4 alky
  • R 7 is hydrogen, C 1 -C 4 alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, —O(C 1 -C 4 alkyl), -C( ⁇ O)(C 1 -C 4 alkyl), —C( ⁇ O)O(C 1 -C 4 alkyl), —OCF 3 , —CF 3 , —CH 2 OH or —CH 2 O(C 1 -C 2 alkyl);
  • halo e.g., chloro, fluoro, iodo or bromo
  • R 10 is hydrogen, hydroxy, methoxy or fluoro
  • R 11 is hydrogen or C 1 -C 4 alkyl
  • A is nitrogen or CR 7 ;
  • B is —NR 1 R 2 , —CR 1 R 2 R 2 R 10 , —C( ⁇ CR 2 R 11 )R 1 , —NHCR 1 R 2 R 10 , —OCR 1 R 2 R 10 , —SCR 1 R 2 R 10 , —CR 2 R 10 NHR 1 , —CR 2 R 10 OR 1 , —CR 2 R 10 SR 1 or —COR 2 ;
  • G is nitrogen or CR 4 and is single bonded to all atoms to which it is attached, or G is carbon and is double bonded to K;
  • K is nitrogen or CR 6 when double bonded to G or E, or K is oxygen, sulfur, C ⁇ O, C ⁇ S, CR 6 R 2 or NR 8 when single bonded to both adjacent ring atoms, or K is a two atom spacer, wherein one of the two ring atoms of the spacer is oxygen, nitrogen, sulfur, C ⁇ O, C ⁇ S, CR 6 R 12 , NR 6 or CR 6, and the other is CR 6 R 12 or CR 9 ;
  • D and E are each, independently, C ⁇ O, C ⁇ S, sulfur, oxygen, CR 4 R 6 or NR 8 when single bonded to both adjacent ring atoms, or nitrogen or CR 4 when it is double bonded to an adjacent ring atom;
  • the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C ⁇ O or C ⁇ S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring;
  • R 1 is C 1 -C 6 alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C 1 -C 4 alkoxy, CF 3 , —C( ⁇ O)(C 1 -C 4 alkyl), —C( ⁇ O)—O-(C 1 -C 4 )alkyl, —OC( ⁇ O)(C 1 -C 4 alkyl), —OC( ⁇ O)N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —NHCO(C 1 -C 4 alkyl), —COOH, —COO(C 1 -C 4 alkyl), —CONH(C 1 -C 4 alkyl), —CON(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —S(C 1 -C 4 alkyl), —CN, —NO 2 ,
  • R 2 is C 1 -C 12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C 1 -C 4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C 1 -C 4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C 3 -C 8 cycloalkyl or (C 1 -C 6 alkylene)(C 3 -C 8 cycloalkyl), wherein one or two of the carbon atoms of said cyclo
  • —NR 1 R 2 or CR 1 R 2 R 10 may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ 2 wherein Z 2 is hydrogen, benzyl or C 1 -C 4 alkyl;
  • R 3 is hydrogen, C 1 -C 4 alkyl, —O(C 1 -C 4 alkyl), chloro, fluoro, bromo, iodo, —S(C 1 -C 4 alkyl) or —SO 2 (C 1 -C 4 alkyl);
  • each R 8 , R 9 and R 12 is selected, independently, from hydrogen and C 1 -C 2 alkyl;
  • each R 4 and R 6 that is attached to a carbon atom is selected, independently, from hydrogen and C 1 -C 6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxy (C 1 -C 2 alkyl), trifluoromethyl, cyano, amino, nitro, —O(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl)(C 1 -C 2 alkyl), —CH 2 SCH 3 , —S(C 1 -C 4 alkyl), —CO(C 1 -C 4 alkyl), —C( ⁇ O)H or —C( ⁇ O)O(C 1 -C 4 alkyl), wherein each of the C 1 -C 2 alkyl moieties in the foregoing R 4 and R 6 groups may optionally contain one double or triple bond; and R 6 , when attached to a nitrogen atom, is selected from hydrogen and C 1 -C 4 alkyl
  • R 5 is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R 5 groups is substituted with from two to four substituents R 13 , wherein up to three of said substituents may be selected, independently, from chloro, C 1 -C 6 alkyl, —O(C 1 -C 6 alkyl) and -(C 1 -C 6 alkylene)O(C 1 -C 6 alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, —NH(C 1 -C 4 alkyl), —N(C 1 -C 2 alkyl)(C 1 -C6 alkyl), —C( ⁇ O)O(C 1 -C 4 alkyl), —C( ⁇ O)(C 1 -C 4 alkyl), —COOH
  • R 7 is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, —C( ⁇ O)(C 1 -C 2 alkyl), —C( ⁇ O)O(C 1 -C 2 alkyl), hydroxymethyl, trifluoromethyl or formyl;
  • halo e.g., chloro, fluoro, iodo or bromo
  • R 10 is hydrogen, hydroxy, methoxy or fluoro
  • R 11 is hydrogen or C 1 -C 4 alkyl
  • the CRF antagonist may also be of the following formula, disclosed in WO 95/10506:
  • R 1 is independently selected at each occurrence from the group consisting of C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, halogen, C 1 -C 2 haloalkyl, NR 6 R 7 , OR 8 , and S(O) n R 8 ;
  • R 3 is C 1 -C 4 alkyl, aryl, C 3 -C 6 cycloalkyl, C 1 -C 2 haloalkyl, halogen, nitro, NR 6 R 7 , OR 8 , S(O) n R 8 C( ⁇ O)R 9 , C( ⁇ O)NR 6 R 7 , C( ⁇ S)NR 6 R 7 , -(CHR 16 ) k NR 6 R 7 , (CH 2 ) k OR 8 , C( ⁇ O)NR 10 CH(R 11 )CO 2 R 12 , —C(OH)(R 25 )(R 25a ),
  • M is CR 5 or N
  • V is CR 1a or N
  • Z is CR 2 or N
  • R 1a , R 2 , and R 3a are independently selected at each occurrence from the group consisting of hydrogen, halo, halomethyl, C 1 -C 3 alkyl, and cyano;
  • R 4 is (CH 2 ) m OR 16 , C 1 -C 4 alkyl, allyl, propargyl, (CH 2 ) m R 13 , or —(CH 2 ) m OC(O)R 16 ;
  • X is halogen, aryl, heteroaryl, S(O) 2 R 8 , SR 8 , halomethyl, —(CH 2 ) p OR 8 , cyano, —(CHR 16 ) p NR 14 R 15 , —C( ⁇ O)R 8 , C 1 -C 6 alkyl, C 4 -C 10 cycloalkylalkyl, C 1 -C 10 alkenyl, C 1 -C 10 alkynyl, C 2 -C 10 alkoxy, aryl-(C 2 -C 10 )-alkyl, C 3 -C 6 cycloalkyl, aryl-(C 1 -C 10 )-alkoxy, nitro, thio-(C 1 -C 10 )-alkyl, —C( ⁇ NOR 16 )-C 1 -C 4 -alkyl, —C( ⁇ NOR 16 )H, or —C( ⁇ O)NR 14
  • X′ is independently selected at each occurrence from the group consisting of hydrogen, halogen, aryl, heteroaryl, S(O) n R 8 , halomethyl, —(CHR 16 ) p OR 8 , cyano, —(CHR 16 ) p NR 14 R 15 , C( ⁇ O)R 8 , C 1 -C 6 alkyl, C 2 -C 10 alkenyl, C c -C 10 alkynyl, C 1 -C 10 alkoxy, aryl-(C 1 -C 1 )-alkyl, C 3 -C 6 cycloalkyl, aryl-(C 1 -C 10 )-alkoxy, nitro, thio-(C 1 -C 10 )-alkyl, —C( ⁇ NOR 16 )-C 1 C 4 -alkyl, —C( ⁇ NOR 16 )H, and —C( ⁇ O)NR 14 R 15 , where substitution by
  • R 5 is halo, —C( ⁇ NOR 16 )-C 1 -C 4 -alkyl, C 1 -C 4 alkyl, C 1 -C 3 haloalkyl, —(CHR 16 ) p OR 8 , —(CHR 16 ) p S(O),R 8 , —(CHR 6 ) p NR 14 R 15 , C 3 -C 6 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl-(C 2 -C 10 )-akyl, aryl-(C 1 -C 10 )-alkoxy, cyano, C 3 -C 6 cycloalkoxy, nitro, amino- (C 2 -C 10 )-alkyl, thio-(C 2 -C 10 )-alkyl, SO n (R 8 ), C( ⁇ O)R 8 -C( ⁇ NOR 16 )
  • R 6 and R 7 are independently selected at each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, C 1 -C 6 alkoxy, (C 4 -C 12 )-cycloalkylalkyl, —(CH 2 ) k R 13 , (CHR 16 ) p OR 8 , -(C 1 -C 6 alkyl)-aryl, heteroaryl, —S(O) z -aryl or -(C 1 -C 6 alkyl)-heteroaryl or aryl, wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, amino, NHC( ⁇ O)(C 1 -C 6 alkyl), NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl), N(
  • A is CH 2 , O, NR 25 C( ⁇ O), S(O) n , N(C( ⁇ O)R 17 ), N(R 19 ), C(H)(NR 14 R 15 ) C(H)(OR 20 ), C(H)(C( ⁇ O)R 21 ), or N(S(O) n R 21 );
  • R 8 is independently selected at each occurrence from the group consisting of hydrogen; C 1 -C 6 alkyl; -(C 4 -C 12 ) cycloalkylalkyl; (CH 2 ) t R 22 ; C 3 -C 10 cycloalkyl; —NR 6 R 7 ; aryl; heteroaryl; —NR 16 (CH 2 ) n R 6 R 7 ; —(CH 2 ) k R 25 ; and (CH 2 ) t heteroaryl or (CH 2 ) t aryl, either of which can optionally be substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, amino, NHC( ⁇ O)(C 1 -C 6 alkyl), NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , nitro, carboxy, CO 2 (C 1 -C 6 alkyl)
  • R 9 is independently selected at each occurrence from R 10 , hydroxy, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 4 alkenyl, aryl substituted with 0-3 R 18, and -(C 1 -C 6 alkyl)-aryl substituted with 0-3 R 18 ;
  • R 10 , R 16 , R 24 , and R 2 are independently selected at each occurrence from hydrogen or C 1 -C 4 alkyl;
  • R 11 is C 1 -C 4 alkyl substituted with 0-3 groups chosen from the following: keto, amino, sulfhydryl, hydroxyl, guanidinyl, p-hydroxyphenyl, imidazolyl, phenyl, indolyl, and indolinyl, or, when taken together with an adjacent R 10 , are (CH 2 ) t ;
  • R 12 is hydrogen or an appropriate amine protecting group for nitrogen or an appropriate carboxylic acid protecting group for carboxyl
  • R 13 is independently selected at each occurrence from the group consisting of CN, OR 19 , SR 19 , and C 3 -C 6 cycloalkyl;
  • R 14 and R 15 are independently selected at each occurrence from the group consisting of hydrogen, C 4 -C 10 , cycloalkyl-alkyl, and R 19 ;
  • R 17 is independently selected at each occurrence from the group consisting of R 10 , C 1 -C 4 alkoxy, halo, OR 23 , SR 23 , NR 23 R 24 , and (C 1 -C 6 ) alkyl (C 1 -C 4 ) alkoxy;
  • R 18 is independently selected at each occurrence from the group consisting of R 10 , hydroxy, halogen, C 1 -C 2 haloalkyl, C 1 -C 4 alkoxy, C( ⁇ O)R 24 , and cyano;
  • R 19 is independently selected at each occurrence from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, (CH 2 ) w R 22 , and aryl substituted with 0-3 R 18 ;
  • R 20 is independently selected at each occurrence from the group consisting of R 10 , C( ⁇ O)R 31 , and C 2 -C 4 alkenyl;
  • R 21 is independently selected at each occurrence from the group consisting of R 10 , C 1 -C 4 alkoxy, NR 23 R 24 , and hydroxyl;
  • R 22 is independently selected at each occurrence from the group consisting of cyano, OR 24 , SR 24 , NR 23 R 24 , C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —S(O) n R 31 , and —C( ⁇ O)R 25 ;
  • R 25 which can be optionally substituted with 0-3 R 17 , is independently selected at each occurrence from the group consisting of phenyl, pyrazolyl, imidazolyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 4-pyrazinyl, azetidinyl, 1H-indazolyl, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl 4aH-carbazolyl, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, azepinyl, be
  • R 25a which can be optionally substituted with 0-3 R 17 , is independently selected at each occurrence from the group consisting of H and R 25 ;
  • R 27 is independently selected at each occurrence from the group consisting of C 1 -C 3 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkoxy, aryl, nitro, cyano, halogen, aryloxy, and heterocycle optionally linked through 0;
  • R 31 is independently selected at each occurrence from the group consisting of C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl, C 4 -C 10 cycloalkyl-alkyl, and aryl-(C 1 -C 4 ) alkyl;
  • k, m, and r are independently selected at each occurrence from 1-4;
  • n is independently, selected at each occurrence from 0-2,
  • p, q, and z are independently selected at each occurrence from 0-3;
  • t and w are independently selected at each occurrence from 1-6,
  • R 5 can not be methyl when X is OH and X′ is H;
  • R 5 can not be —NHCH 3 , or —N(CH 3 ) 2 when X and X′ are—OCH 3 ;
  • R 5 can not be —N(CH 3 ) 2 when X and X′ are —OCH 2 CH 3 ;
  • R 5 can not be methylamine when X and X′ are —OCH 3 ;
  • R 5 can not be OH when X is Br and X′ is OH;
  • R 5 can not be —CH 2 OH or —CH 2 N(CH 3 ) 2 when X is —SCH 3 and X′is H;
  • R 3 can not be OH, piperazin-1-yl, —CH 2 ,-piperidin-1-yl, —CH 2 -(N-4-methylpiperazin-1-yl), —C(O)NH-phenyl, —CO 2 H, —CH 2 O-(4-pyridyl), —C(O)NH 2 , 2-indolyl, —CH 2 O-(4-carboxyphenyl), —N(CH 2 CH 3 )(2-bromo-4-isopropylphenyl);
  • R 2 is —CH 2 CH 2 CH 3 then R 3 can not be —CH 2 CH 2 CH 3
  • R 5 is iso-propyl, X is bromo, and X′ is H, then
  • R 3 can not be OH or —OCH 2 CN when R 1 is CH 3 and
  • R 3 can not be —N(CH 3 ) 2 when R 1 is —N(CH 3 ) 2 ;
  • R 5 is —OCH 3
  • X is —OCH 3
  • X′ is H
  • R 3 and R 1 can not both be chloro; further provided that when J, K, and L are all CH and M is CR 5 , then
  • (H) Z can be N only when both V and Y are N or when V is CR 1a and Y is CR 3a ;
  • R 3 can not be 2-pyridinyl, indolyl, indolinyl, imidazolyl, 3-pyridinyl, 4-pyridinyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, or 4-pyrazinyl;
  • J, K, L, M, Z, A, k, m, n, p, q, r, t, w, R 3 , R 10 , R 11 , R 12 , R 13 , R 16 , R 18 , R 19 , R 21 , R 23 , R 24 , R 25 , and R 27 are as defined above and R 25a , in addition to being as defined above, can also be C 1 -C 4 alkyl, but
  • V is N
  • R 1 is C 1 -C 2 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 2 -C 4 alkoxy, halogen, amino, methylamino, dimethylamino, aminomethyl, or N-methylaminomethyl;
  • R 2 is independently selected at each occurrence from the group consisting of hydrogen, halo, C 1 -C 3 , alkyl, nitro, amino, and —CO 2 R 10 ;
  • R 4 is taken together with R 29 to form a 5-membered ring and is —C(R 26 ) ⁇ or —N ⁇ when R 29 is —C(R 30 ) ⁇ or —N ⁇ , or —CH(R 26 )— when R 29 is —CH(R 30 )—;
  • X is Cl, Br, I, S(O)nR 8 , OR 8 , halomethyl, —(CHR ) p OR 8 , cyano, —(CHR 16 ) p NR 14 R 15 , C( ⁇ O)R 8 , C 1 -C 6 alkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 1 -C 10 , alkoxy, aryl-(C 1 -C 10 )-alkyl, C 3 -C 6 cycloalkyl, aryl-(C 1 -C 10 )-alkoxy, nitro, thio-(C 1 -C 10 )-alkyl, —C( ⁇ NOR 16 )-C 1 —C 4 -alkyl, —C( ⁇ NOR 16 )H, or C( ⁇ O)NR 14 R 15 where substitution by R 18 can occur on any carbon containing substituents;
  • X′ is hydrogen, Cl, Br, I, S(O) n R 8 , —(CHR 16 ) p OR 8 , halomethyl, cyano, —(CHR 16 ) p NR 14 R 15 , C( ⁇ O)R 8 , C 1 -C 6 alkyl, C 2 -C 10 alkenyl, C 1 -C 10 alkoxy, aryl-(C 1 -C 10 )-alkyl, C 3 -C 6 cycloalkyl, aryl-(C 2 -C 10 )-alkoxy, nitro, thio-(C 2 -C 10 )-alkyl, —C( ⁇ NOR 16 )-C 1 -C 4 -alkyl, —C( ⁇ NOR 16 )H, or C( ⁇ O)NR 8 R 15 where substitution by R 18 can occur on any carbon containing substituents;
  • R 5 is halo, —C( ⁇ NOR 16 )-C 1 -C 4 -alkyl, C 1 -C 6 alkyl, C 1 -C 3 haloalkyl, C 1 -C 6 alkoxy, (CHR 16 ) p OR 5 , (CHR 16 ) p S(O) n R 8 , (CHR 16 ) p NR 14 R 15 , C 3 -C 6 cycloalkyl, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, aryl-(C 2 -C 10 )-alkyl, aryl-(C 1 -C 10 )-alkoxy, cyano, C 3 -C 6 cycloalkoxy, nitro, amino-(C 1 -C 10 )-alkyl, thio-(C 1 -C 10 )-alkyl, SO n (R 8 ), C( ⁇ O)R 8 ,
  • R 6 and R 7 are independently selected at each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 10 cycloalkyl, —(CH 2 ) k R 13 , (C 4 -C 12 )-cycloalkylalkyl, C 1 -C 6 alkoxy, -(C 1 -C 6 alkyl)-aryl, heteroaryl, aryl, —S(O),-aryl or -(C 1 -C 6 alkyl)-heteroaryl or aryl wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, amino, NHC( ⁇ O)(C 1 -C 6 alkyl), NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , nitro, carboxy, CO 2 (C 1 -
  • R 8 is independently selected at each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, -(C 4 -C 12 ) cycloalkylalkyl, (CH 2 )R 22 , C 3 -C 10 cycloalkyl, -(C 1 -C 6 alkyl)-aryl, heteroaryl, —NR 16 , —N(CH 2 ) n NR 6 R 7 ; —(CH 2 ) k R 25 , -(C 1 -C 6 alkyl)-heteroaryl or aryl optionally substituted with 1-3 groups selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, amino, NHC( ⁇ O)(C 1 -C 6 alkyl), NH(C 1 -C 6 alkyl), N(C 1 -C 6 alkyl) 2 , nitro, carboxy, CO 2 (C 1 -C 6 alkyl
  • R 9 is independently selected at each occurrence from R 10 , hydroxy, C 1 -C 4 alkoxy, C 3 -C 6 cycloalkyl, C 2 -C 4 alkenyl, and aryl substituted with 0-3 R 18 ;
  • R 14 and R 15 are independently selected at each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, (CH 2 ) t R 22 , and aryl substituted with 0-3 R 18 ;
  • R 17 is independently selected at each occurrence from the group consisting of R 10 , C 1 -C 4 alkoxy, halo, OR 23 , SR 23 , and NR 23 R 24 ;
  • R 20 is independently selected at each occurrence from the group consisting of R 10 and C( ⁇ O)R 31 ;
  • R 22 is independently selected at each occurrence from the group consisting of cyano, OR 24 , SR 24 , NR 23 R 24 , C 3 -C 6 cycloalkyl, —S(O) n R 31 , and —C( ⁇ O)R 25 ;
  • R 26 is hydrogen or halogen
  • R 28 is C 1 -C 2 , alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, hydrogen, C 1 -C 2 alkoxy, halogen, or C 2 -C 4 alkylamino;
  • R 29 is taken together with R 4 to form a five membered ring and is: —CH(R 30 )— when R 4 is —CH(R 28 )—, —C(R 30 ) ⁇ or —N ⁇ when R 4 is —C(R 28 ) ⁇ or —N ⁇ ;
  • R 30 is hydrogen, cyano, C 1 -C 2 alkyl, C 1 -C 2 alkoxy, halogen, C 1 -C 2 alkenyl, nitro, amido, carboxy, or amino;
  • R 31 is C 1 -C 4 alkyl, C 3 -C 7 cycloalkyl, or aryl-(C 1 -C 4 ) alkyl; provided that when J, K, and L are all CH, M is CR 5 , Z is CH, R 3 is CH 3 , R 28 is H, R 5 is isopropyl, X is Br, X′ is H, and R 1 is CH 3 , then R 30 can not be H, —CO 2 H, or —CH 2 NH 2 ; and further provided that when J, K and L are all CH; M is CR 5 ; Z is N; and
  • R 29 is —C(R 30 ) ⁇ ; then one of R 28 or R 30 is hydrogen;
  • R 29 is N; then R 3 is not halo, NH 2 , NO 2 , CF 3 , CO 2 H, CO 2 -alkyl, alkyl, acyl, alkoxy, OH, or —(CH 2 ) m Oalkyl;
  • R 29 is N; then R 28 is not methyl if X or X′ are bromo or methyl and R 5 is nitro; or
  • R 29 is N; and R 1 is CH 3 ; and R 3 is amino; then R 5 is not halogen or methyl.
  • Preferred compounds of this group include those wherein:
  • V is N, R 1 is methyl; and R 3 is aryl, NR 6 R 7 , or OR 8 ;
  • V is N, R 1 is methyl; R 3 is aryl, NR 6 R 7 , or OR 8 ; and R 4 is methyl or ethyl;
  • V is N, R 1 is methyl; R 3 is aryl, NR 6 R 7 , or OR 8 ; R 4 is methyl or ethyl; and X is O(C 1 -C 4 alkyl), Br, or C 1 -C 4 alkyl;
  • V is N, R 1 is methyl; R 3 is aryl, NR 6 R 7 , or OR 8 ; R 4 is methyl, ethyl; X is OMe, Br, or (C 1 -C 4 alkyl), M is C 1 -C 4 alkyl, Br, Cl, or O(C 1 -C 4 alkyl); and
  • V is N, R 1 is methyl; R 3 is aryl, NR 6 R 7 , OR 8 ; or R 4 is methyl, ethyl; X is OMe, Br, or C 1 -C 4 alkyl, M is C 1 -C 4 alkyl, Br, Cl, or O(C 1 -C 4 alkyl); and L is CH, or N.
  • each of R 1 and R 2 is independently a halogen atom; a C 1- C 5 hydroxyalkyl radical; C 1 -C 5 alkyl; C 7 -C 10 aralkyl; C 1 -C 5 alkoxy; trifluoromethyl; nitro; nitrile; a group —SR where R is hydrogen, a C 1 -C 5 alkyl radical or a C 7 -C 10 aralkyl radical; a group S—CO—R where R is a C 1 -C 5 alkyl radical or aralkyl in which the aryl portion is C 6 -C 8 and the alkyl portion is C 1 -C 4 ; a group —COOR′ where R′ is hydrogen or C 1 -C 5 alkyl; a group —CONR′R′′ where R′ and R′′ are as defined above for R′; a group —NR′R′′ where R′ and R′′ are as previously defined for R′; a group —
  • CRF antagonists of the following formula, disclosed in WO 97/29109, may also be employed:
  • R 1 is NR 4 R 5 or OR 5 ;
  • R 2 is C 1 -C 6 alkyl, C 1 -C 6 alkyloxy or C 1 -C 6 alkylthio,
  • R 3 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfoxy or C 1 -C 6 alkylthio;
  • R 4 is hydrogen, C 1 -C 6 alkyl, mono- or di(C 3 -C 6 cyloalkylmethyl, C 3 -C 6 cyloalkyl, C 3 -C 6 alkenyl, hydroxyC 1 -C 6 alkyl, C 1 -C 6 akylcarbonyloxyC 1 -C 6 alkyl or C 1 -C 6 alkyloxyC 1 -C 6 alkyl;
  • R 5 is C 1 -C 8 alkyl, mono- or di(C 3 -C 6 cycloalkyl)methyl, Ar 1 CH 2 , C 3 -C 6 alkenyl, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl, thienylmethyl, furanylmethyl, C 1 -C 6 alkylthioC 1 -C 6 alkyl, morpholinyl, mono- or di(C 1 -C 6 alkyl)aminoC 1-6 alkyl, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkylcarbonylC 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar 1 ;
  • R 4 and R 5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C 1 -C 6 alkyl or C 1 -C 6 alkyloxyC 1 -C 6 alkyl; and
  • Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C 1 -C 6 alkyl, trifluoromethyl, hydroxy, cyano, C 1 -C 6 alkyloxy, benzyloxy, C 1 -C 6 alkylthio, nitro, amino and mono- or di(C 1 -C 6 alkyl)amino; pyridinyl; pyridinyl substituted with I ⁇ 2 or 3 substituents independently selected from halo, C 1 -C 6 alkyl, trifluoromethyl, hydroxy, cyano, C 1 -C 6 alkyloxy, benzyloxy, C 1 -C 6 alkylthio, nitro, amino, mono- or di(C 1 -C 6 alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;
  • Ar 1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, di(C 1 -C 6 alkyl)aminoC 1 -C 6 alkyl, trifluoromethyl and C 1 -C 6 alkyl substituted with morpholinyl; or pyridinyl; and Alk is C 1 -C 6 alkanediyl; with the proviso that 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included.
  • Preferred compounds of this formula are those wherein R 2 is methyl; R 3 is hydrogen, or C 1 -C 6 alkyl; and Ar is substituted phenyl or 3-pyridyl.
  • X is S. SO or SO 2 ;
  • R 1 is NR 4 R 5 or OR 5 ;
  • R 2 is C 1 -C 6 alkyl, C 1 -C 6 alkyloxy or C 1 -C 6 alkylthio;
  • R 3 is hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkylsulfoxy or C 1 -C 6 alkylthio;
  • R 4 is hydrogen, C 1-6 alkyl, mono- or di(C 3 -C 6 cycloalkyl)methyl, C 3 -C 6 cycloalkyl, C 3 -C 6 alkenyl, hydroxyC 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyloxyC 1 -C 6 alkyl or C 1 -C 6 alkyloxyC 1 -C 6 alkyl;
  • R 5 is C 1 -C 8 alkyl, mono- or di(C 3 -C 6 cycloalkyl)methyl, Ar 1 CH 2 , C 3 -C 6 alkenyl, C 1 -C 6 alkyloxyC 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl, thienylmethyl, furanylmethyl, C 1 -C6alkylthioC 1 -C 6 alkyl, morpholinyl, mono- or di(C 1 -C 6 alkyl)aminoC 1 -C 6 alkyl, di(C 1 -C 6 alkyl)amino, C 1 -C 6 alkylcarbonylC 1 -C 6 alkyl, C 1 -C 6 alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar I; or R 4 and R 5 taken together with the nitrogen atom to which they are attached may form a pyrroli
  • Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C 1 -C 6 alkyl, trifluoromethyl, hydroxy, cyano, C 1 -C 6 alkyloxy, benzyloxy, C 1 -C 6 alkylthio, nitro, amino and mono- or di(C 1 -C 6 alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C 1 -C 6 alkyl, trifluoromethyl, hydroxy, cyano, C 1 -C 6 alkyloxy, benzyloxy, C 1 -C 6 alkylthio, nitro, amino, mono- or di(C 1 -C 6 alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;
  • Ar 1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C 1 -C 6 alkyl, C 1 -C 6 alkyloxy, di(C 1 -C 6 alkyl)aminoC 1 -C 6 alkyl trifluoromethyl, and C 1 -C 6 alkyl substituted with morpholinyl; or pyridinyl; and
  • Alk is C 1 -C 6 alkanediyl.
  • Preferred compounds of this group include those wherein:
  • R 2 is methyl
  • R 2 is methyl; and Ar is substituted phenyl or 3-pyridyl;
  • R 2 is methyl; R 3 is methyl; and Ar is substituted phenyl or 3-pyridyl.
  • CRF antagonists useful in the practice of the invention include, without limitation, the following compounds:
  • chlorhydrate de 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-bromo-2-methoxynaphth-1-yl)-N-propylamino]thiazole;
  • the present invention relates to a pharmaceutical composition for the treatment of a condition selected from the group consisting of:
  • the composition comprises an amount of a CRF antagonist effective to treat the condition in combination with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier Where the condition is depression, it is also treated with a second compound for treating depression, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist.
  • the present invention relates to a method for treating or preventing a cardiovascular disease that involves administering a CRF antagonist, or a pharmaceutically acceptable salt, isomer, or prodrug thereof, in combination with a second, non-CRF antagonist compound for treating the disease.
  • the second compound for treating the disease can be, for example, adenosine, alteplase, amiodarone, anagrelide, ardeparin, argatroban, atenolol, atorvastatin, benazepril, captopril, carvedilol, cerivastatin, clonidine, clopidrogrel, dalteparin, danaparoid, diltiazem, enalapril, fluvastatin, fosinopril, gemfibrozil, hydrochlorothiazide, irbesartan, lepirudin, lisinopril, lovastatin, oprelvekin, pravastatin, prazosin, quinapril, ramipril, saruplase, simvastatin, terazosin, valsartan, or verapamil.
  • the invention relates to treatment of migraine or non-migraine headache by administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition.
  • a CRF antagonist with non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, acetaminophen, ibuprofen, with anti-emetics, with preparations containing ergotamine such as dihydroergotamine, or with agents that modulate serotonin receptors (including those that modulate the 5HT 1B , 5HT 1D , 5HT 1F and 5HT 2B receptors) or that mimic the effects of serotonin.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • agents include sumatriptan, naratriptan, zolmitriptan, rizatriptan, eletriptan, and almotriptan.
  • Administration of these compounds is carried out using dosages and formulations that are well-known.
  • the invention relates to treatment of emesis using a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis.
  • non-CRF antagonist compounds for treating emesis include tachykinin antagonists, including Nk1 antagonists, (such as compounds described in WO 99/24423, EP 867182, EP 980324, and WO 99/24423) and 5HT 3 antagonists (such as metoclopramide, granisetron, dolasetron, ondansetron and tropisetron).
  • the emesis that is treated can be of any type, including emesis induced by pregnancy, vestibular disorder, post-operative sickness, gastrointestinal obstruction, reduced gastrointestinal motility, visceral pain, migraine, change in intercranial pressure, chemotherapy, radiation, toxins, and opioid analgesics.
  • the invention also encompasses combined pharmaceutical compositions containing the CRF antagonist, a non-CRF antagonist as defined above, and below, and a pharmaceutically acceptable carrier.
  • examples of such compositions include, without limitation:
  • composition for treating abnormal circadian rhythm that contains effective amounts of a combination of a CRF antagonist and a non-CRF antagonist compound useful for treating abnormal circadian rhythm;
  • composition for treating depression that contains effective amounts of a combination of a CRF antagonist and a second compound for treating depression that has a delayed effect
  • composition for treating or preventing a cardiovascular disease that contains effective amounts of a CRF antagonist in combination with a second, non-CRF antagonist compound for treating the disease;
  • composition for treating migraine or non-migraine headache that contains effective amounts of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition;
  • composition for treating emesis that contains a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis.
  • Combination treatments according to the invention can be administered as part of the same pharmaceutical composition, or the active agents can be administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy.
  • Acid addition salts of the CRF antagonists and other agents employed in the invention can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques can be employed to isolate the salts.
  • Suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids.
  • the CRF antagonists and their pharmaceutically acceptable salts, and any second pharmaceutically active compounds may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses.
  • suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, oils (e.g., peanut oil, sesame oil) and various organic solvents.
  • the pharmaceutical compositions formed by combining the CRF antagonists and pharmaceutically acceptable carriers can be readily administered in a variety of dosage forms such as tablets, powders, lozenges, emulsions, oil soft gels, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.
  • solutions containing the CRF antagonist or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art.
  • the effective dosages for the CRF antagonists employed in the methods of this invention will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician.
  • the dosages will also depend on the particular condition to be treated and will generally range from about 0.1 to about 300 mg/kg body weight of the patient per day, with administration carried out in single or divided dosages.

Abstract

A corticotropin releasing factor (CRF) antagonist is administered to treat a condition selected from the group consisting of:
c) disorders that can be treated by altering circadian rhythm; and
d) depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist.

Description

    FIELD OF THE INVENTION
  • This invention relates to the use of CRF antagonists in the treatment of certain conditions, and related compositions. [0001]
    • BACKGROUND OF THE INVENTION
  • CRF antagonists are disclosed in U.S. Pat. Nos. 4,605,642 (Issued Aug. 12, 1986) and 5,063,245 (issued Nov. 5, 1991). They are also disclosed in International patent publications WO 95/33750 (published Dec. 14, 1995); WO 95/34563 (published Dec. 21, 1995); WO 94/13676 (published Jun. 23, 1994); WO 94/13677 (published Jun. 23, 1994); WO 95/33727 (published Dec. 14, 1995); WO 98/05661 (published Feb. 12, 1998); WO 98/08847 (published Mar. 5, 1998); and WO 98/08846 (published Mar. 5, 1998) and European patent publications EP 778277 (published Jun. 11, 1997) and EP 773023 (published May 14, 1997). CRF antagonists are also disclosed in the following patent publications: EP 576350; WO 95/10506 (published Apr. 20, 1995); WO 96/35689 (published Nov. 14, 1996); WO 96/39400 (published Dec.12, 1996); WO 97/00868 (published Jan. 9, 1997); WO 97/14684 (published Apr. 24, 1997); WO 97/29109 (published Aug. 14, 1997); WO 97/29110 (published Aug. 14, 1997); WO 97/35580 (published Oct. 2, 1997); WO 97/35846 (published Oct. 2, 1997); WO 97/44038 (published Nov. 27, 1997); WO 98/03510 (published Jan. 29, 1998); WO 98/08821 (published Mar. 5, 1998); WO 98/11075 (published Mar. 19, 1998); WO 98/15543 (published Apr. 16, 1998); WO 98/21200 (published May 22, 1998); WO 98/27066 (published Jun. 25, 1998); WO 98/29397 (published Jul. 9, 1998); WO 98/29413 (published Jul. 9, 1998); WO 98/42699 (published Oct. 1, 1998); WO 98/35967 (published Aug. 20, 1998); WO 98/45295 (published Oct. 15, 1998); WO 98/47874 (published Oct. 29, 1998); WO 98/47903 (published Oct. 29, 1998); WO 99/01454 (published Jan. 14, 1999); WO 99/01439 (published Jan. 14, 1999); WO 99/10350 (published Mar.4, 1999); WO 99/12908 (published Mar. 18, 1999); WO 99/00373 (published Jan. 7, 1999); and WO 99/38868 (published Aug. 5, 1999). [0002]
  • The importance of CRF antagonists is set out in the literature, e.g., P. Black, Scientific American SCIENCE & MEDICINE,1995, p. 16-25; T. Lovenberg, et al., Current Pharmaceutical Design, 1995, 1: 305-316; and U.S. Pat. No. 5,063,245. An outline of the activities possessed by CRF antagonists is found in M. J. Owens et al., 1991, Pharm. Rev., 43:425-473. CRF antagonists are described in the art as being effective in the treatment of stress-related illnesses, mood disorders such as depression, major depressive disorder, single episode depression, recurrent depression, child abuse induced depression, postpartum depression, dysthemia, bipolar disorders, and cyclothymia; chronic fatigue syndrome; eating disorders such as anorexia and bulimia nervosa; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; post-traumatic stress disorder; pain perception such as fibromyalgia; headache; gastrointestinal diseases; hemorrhagic stress; ulcers; stress-induced psychotic episodes; fever; diarrhea; post-operative ileus; colonic hypersensitivity; irritable bowel syndrome; Crohn's disease; spastic colon; inflammatory disorders such as rheumatoid arthritis and osteoarthritis; pain; asthma; psoriasis; allergies; osteoporosis; premature birth; hypertension, congestive heart failure; sleep disorders; neurodegenerative diseases such as Alzheimer's disease, senile dementia of the Alzheimer's type, multiinfarct dementia, Parkinson's disease, and Huntington's disease; head trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; stroke; spinal cord trauma; psychosocial dwarfism; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone; obesity; chemical dependencies and addictions; drug and alcohol withdrawal symptoms; infertility; cancer; muscular spasms; urinary incontinence; hypoglycemia and immune dysfunctions including stress induced immune dysfunctions, immune suppression and human immunodeficiency virus infections; and stress-induced infections in humans and animals. [0003]
    • SUMMARY OF THE INVENTION
  • The present invention relates to a method of treating a condition comprising administering a corticotropin releasing factor (CRF) antagonist in an amount effective to treat the condition, the condition being selected from the group consisting of: [0004]
  • a) disorders that can be treated by altering circadian rhythm; and [0005]
  • b) depression, further wherein a second compound for treating depression is administered, the second compound for treating depression having an onset of action that is delayed with respect to that of the CRF antagonist. [0006]
  • In another aspect, the present invention relates to a method for treating or preventing a cardiovascular disease that involves administering a CRF antagonist in combination with a non-CRF antagonist compound for treating the disease. The invention also relates to treatment of migraine or non-migraine headache by administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition and to treatment of emesis using a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis. [0007]
    • DETAILED DESCRIPTION OF THE INVENTION
  • All patents, patent publications, and literature references cited herein are hereby incorporated by reference. [0008]
  • In one aspect, the present invention provides for treatment of disorders that can be treated by altering circadian rhythm, e.g., abnormal circadian rhythm, by administration of a CRF antagonist. Abnormal circadian rhythm treated according to the invention can be associated with several types of disorders, including, without limitation, time zone change syndrome, seasonal affective disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24 hour sleep wake disorder, light-induced clock resetting, REM sleep disorder, hypersomnia, parasomnia, narcolepsy, nocturnal enuresis, restless legs syndrome, sleep apnea, dysthymia, and abnormal circadian rhythm associated with chronic administration and withdrawal of antidepressant agents. [0009]
  • If desired, a second compound, e.g., a non-CRF antagonist that is useful for treating sleep disorder, can be administered before, with, or after, administration of the CRF antagonist. Any such second compound useful for treating sleep disorder may be employed, including but not limited to tachykinin antagonists, melatoninergic agonists, such as melatonin, GABA brain receptor agonists, serotonin receptor (such as 5HT1b, 5HT2c, 5HT7) antagonists, inverse agonists, agonists and other compounds. Specific compounds for treatment of sleep disorder include melatonin, carpipramine, and doxylamine. These and other compounds are described, for example, in U.S. Pat. Nos. 5,908,932; 5,902,813; 5,883,094; 5,874,450; 5,849,781; 5,856,529; and 4,956,362. [0010]
  • It is intended that reference to particular compounds herein be interpreted to mean that the pharmaceutically acceptable salts and prodrugs of those compounds, may also be employed. Such reference is also intended to be interpreted that modified CRF antagonists may also be employed. For example, the invention encompasses use of a CRF antagonist linked to a non-CRF antagonist to form a prodrug which hydrolyzes upon administration to form active components. [0011]
  • The invention also encompasses treatment of depression with a CRF antagonist and with a second compound having delayed action for treating depression. According to this aspect of the invention, the CRF antagonist initiates treatment of the depression with a quick-acting effect, which treatment is supplemented by the delayed effect of the second compound. [0012]
  • Compounds for treating depression that have a delayed effect include, without limitation, compounds that are selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, norepinephrine reuptake inhibitors, noradrenaline reuptake inhibitors, lithium, α2-adrenoreceptor agonists, 5HT[0013] 1A inhibitors, and monoamine oxidase type A inhibitors. Examples include bupropion, sertraline, fluoxetine, trazodone, citalopram, fluvoxamine, paroxetine, venlafaxine, roboxetine, imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, brofaromine, milnacipran, and buspirone. It understood by those skilled in this art that compounds administered for treatment of depression may have other beneficial effects, such as ameliorating sleep disturbance or sexual dysfunction. Compounds having a delayed effect for treating depression also include the combination of an SSRI and 5HT2 antagonist (such as risperidone) administered, for example, to patients who do not respond to SSRI therapy alone. Administration of these delayed-action compounds for treating depression is carried out using well-known dosages and formulations.
  • Any CRF antagonist can be used to practice the invention, including those that are described in U.S. Pat. Nos. 4,605,642 and 5,063,245; International patent publications WO 95/33750; WO 95/34563; WO 94/13676; W094/13677; WO 95/33727; WO 98/05661; WO 98/08847; and WO 98/08846; and European patent publications EP 778277; and EP 773023. They also include those of the following patent publications: EP 576350; WO 95/10506; WO 96/35689; WO 96/39400; WO 97/00868; WO 97/14684; WO 97/29109; WO 97/29110; WO 97/35580; WO 97/35846; WO 97/44038; WO 98/03510; WO 98/08821; WO 98/11075; WO 98/15543; WO 98/21200; WO 98/27066; WO 98/29397; WO 98/29413; WO 98/42699; WO 98/35967; WO 98/45295; WO 98/47874, WO 98/47903, WO 99/01454, WO 99/01439, WO 99/10350; WO 99/12908; WO 99/00373, and WO 99/38868. As noted above, the texts of all of these publications are incorporated by reference herein in their entireties. [0014]
  • Following are listed particular examples of CRF antagonists that may be used in practicing the invention. It is understood that in the generic formulae employed below, the variables employed, e.g., “A”, “B”, “R[0015] 1”, “R2”, etc. have the meanings attributed to them only in the particular Roman numeral section in which they are found. Thus, the meaning attributed, for example, to “R1” is different for the structures in section I and the structures of the other sections.
    •
  • I. For example, the CRF antagonist may be of the following formula, described in WO 94/13677: [0016]
    Figure US20020156089A1-20021024-C00001
  • and the pharmaceutically acceptable acid addition salts thereof, wherein [0017]
  • A is NR[0018] 1R2, CR1R2R11, or C(═CR1R12)R2, NHCR1R2R11, OCR1R2R11, SCR1R2R11, NHNR1R2, CR2R11NHR1, CR2R11OR1, CR2R11SR1 or C(O)R2;
  • R[0019] 1 is hydrogen, or C1-C6 alkyl which may be substituted by one or two substituents R6 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C1-C6 alkoxy, O—C(O)-(C1-C6 alkyl), O—C(O)—N(C1-C4 alkyl)(C1-C2 alkyl); amino, NH(C1-C4 alkyl, S(C1-C6 alkyl), OC(O)NH(C1-C4 alkyl), N(C1-C2 alkyl)C(O)(C1-C4 alkyl), NHC(O)(C1-C4 alkyl), COOH, CO(C1-C4 alkyl), C(O)NH(C1-C4 alkyl), C(O)N(C1-C4 alkyl)(C1-C2 alkyl), SH, CN, NO2, SO(C1-C4 alkyl); SO2(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), and said C1-C6 alkyl may have one or two double or triple bonds;
  • R[0020] 2 is C1-C12 alkyl, aryl or (C1-C10 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, oxazolyl, or benzoxazolyi; 3- to 8-membered cycloalkyl or (C1-C6 alkylene) cycloalkyl, wherein said cycloalkyl may have one or two of O, S or N—Z, wherein Z is hydrogen, substituted, independently, for one or two carbons of said cycloalkyl, C1-C4 alkyl, benzyl or C1-C4 alkanoyl, wherein R2 may be substituted independently by from one to three of chloro, fluoro, or C1-C4 alkyl, or one of hydroxy, bromo, iodo, C1-C6 alkoxy, OC(O)(C1-C6 alkyl), O—C—N(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C6 alkyl), NH2, NH(C1-C2 alkyl), N(C1-C4 alkyl) C(O)(C1-C4 alkyl), NHC(O)(C1-C4 alkyl), COOH, C(O)O(C1-C4 alkyl), C(O)NH(C1-C4 alkyl), C(O)N(C1-C4 alkyl)(C1-C2 alkyl), SH, CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), and wherein said C1-C12 alkyl or C1-C10 alkylene may have one to three double or triple bonds; or
  • NR[0021] 1R2 or CR1R2R11 may form a 4- to 8-membered ring optionally having one or two double bonds or one or two of O, S or N—Z wherein Z is hydrogen, C1-C4 alkyl, benzyl, or C1-C4 alkanoyl;
  • R[0022] 3 is hydrogen, C1-C6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), SH, S(C1-C4 alkyl), SO(C1-C4 alkyl), or SO2(C1-C4 alkyl), wherein said C1-C4 alkyl and C1-C6 alkyl may have one or two double or triple bonds and may be substituted by from 1 to 3 R7 substituents independently selected from the group consisting of hydroxy, amino, C1-C3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHC(O)CH3, fluoro, chloro or C1-C3 thioalkyl;
  • R[0023] 4 is hydrogen, C1-C6 alkyl, fluoro, chloro, bromo, iodo, C1-C6 alkoxy, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl) (C1-C2 alkyl), SOn(C1-C6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C1-C6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(O)(C1-C4 alkyl), NH(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), C(O)O(C1-C4 alkyl), C1-C3 alkoxy, C1-C3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;
  • R[0024] 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinolyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzoisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, piperazinyl, piperidinyl, or tetrazolyl, wherein each one of the above groups may be substituted independently by from one to three of fluoro, chloro, bromo, formyl, C1-C6 alkyl, C1-C6 alkoxy or trifluoromethyl, or one of hydroxy, iodo, cyano, nitro, amino, cyclopropyl, NH(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), COO(C1-C4 alkyl), CO(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), SO2NH2, NHSO2(C1C4 alkyl), S(C1-C6 alkyl), SO2(C1-C6 alkyl), wherein said C1-C4 alkyl and C1-C6 alkyl may have one double or triple bond and may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R5 is not unsubstituted phenyl;
  • R[0025] 11 is hydrogen, hydroxy, fluoro, chloro, COO(C1-C2 alkyl), cyano, or CO(C1-C2 alkyl); and
  • R[0026] 12 is hydrogen or C1-C4 alkyl;
  • (a) A is not straight chain C[0027] 1-C12 alkyl;
  • (b) when R[0028] 3 is hydrogen, A is benzyl or phenethyl, and R4 is fluoro, chloro, bromo or iodo, then R5 is not 5′-deoxy-ribofuranosyl or 5′-amino-5′-deoxy-ribofuranosyl; and
  • (c) when R[0029] 5 is phenyl, said phenyl is substituted by two or three substituents.
  • II. The invention also relates to use of a CRF antagonist of the following formula, described in WO 94113676: [0030]
    Figure US20020156089A1-20021024-C00002
  • and the acid addition salts thereof, wherein [0031]
  • B is XA wherein X is (CH[0032] 2)n in which n is 0, 1 or 2, NH, O, S, N(C1-C4 alkyl);
  • A is NR[0033] 1R2, CR1R2R11, or C(═CR2R12)R1;
  • R[0034] 1 is hydrogen, or C1-C6 alkyl which may be substituted by one or two substituents R7 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C1-C8 alkoxy, O—C(=O)-(C1-C6 alkyl), O—C(═O)NH(C1-C4 alkyl), O—C(═O)—N(C1-C4 alkyl)(C1-C2 alkyl), amino, NH(C1-C4 alkyl), N(C1-C2 alkyl)(C1-C4 alkyl), S(C1-C6 alkyl), N(C1-C4alkyl)C(═O)(C1-C4 alkyl), NH(C1-C4 alkyl), COOH, C(═O)O(C1-C4 alkyl), C(═O)NH(C1-C4 alkyl), C(═O)N(C1-C4 alkyl)(C1-C2 alkyl), SH, CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), and said C1-C6 alkyl may contain one or two double or triple bonds;
  • R[0035] 2 is C1-C12 alkyl, aryl or (C1-C10 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl, or benzoxazolyl; 3-8-membered cycloalkyl or (C1-C6 alkylene) cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N—Z wherein Z is hydrogen, C1-C4 alkyl, benzyl or C1-C4 alkanoyl, wherein R2 may be substituted independently by from one to three of chloro, fluoro, or C1-C4 alkyl, or one of hydroxy, bromo, iodo, C1-C6 alkoxy, O—C(═O)-(C1-C6 alkyl), O—C—N(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C6 alkyl), NH2, NH(C1-C2 alkyl), N(C1-C2 alkyl)(C1-C4 alkyl), N(C1-C4)-C(═O)(C1-C4 alkyl), NHC(═O)(C1-C4), COOH, C(═O)O(C1-C4 alkyl), C(═O)NH(C1-C4 alkyl), C(═O)N(C1-C4 alkyl)(C1-C2 alkyl), SH, CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), and wherein said C1-C12 alkyl or C1-C10 alkyl may contain one to three double or triple bonds; or
  • when A is NR[0036] 1R2 or CR1R2R11, then R1 and R2 taken together with the atom to which they are attached may form a saturated 4- to 8-membered optionally containing one or two double bonds or one or two of O, S or N—Z wherein Z is hydrogen, C1-C4 alkyl, or C1-C4 alkanoyl;
  • R[0037] 3 is hydrogen, C1-C6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, amino, O(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), SH, S(C1-C4 alkyl), SO(C1-C4 alkyl), or SO2(C1-C4 alkyl), wherein said C1-C4 alkyl and C1-C6 alkyl may contain from one or two double or triple bonds and may be substituted by from 1 to 3 substituents R8 independently selected from the group consisting of hydroxy, amino, C1-C3 alkoxy, dimethylamino, diethylamino, methylamino, ethylamino, NHCH3, fluoro, chloro or C1-C3 thioalkyl;
  • R[0038] 4 and R6 are each independently hydrogen, C1-C6 alkyl, fluoro, chloro, bromo, iodo, C1-C6 alkoxy, amino, NH(C1-C6 alkyl), N(C1-C6 alkyl)(C1-C2 alkyl), SOn(C1-C6 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, carboxy, or amido, wherein said C1-C6 alkyls may be substituted by one to three of hydroxy, amino, carboxy, amido, NHC(═O)(C1-C4 alkyl), NH(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), C(═O)O(C1-C4 alkyl), C1-C3 alkoxy, C1-C3 thioalkyl, fluoro, bromo, chloro, iodo, cyano or nitro;
  • R[0039] 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, azaindolyl, benzoxazolyl, oxazolyl, pyrrolidinyl, thiazolidinyl, morpholinyl, piperidinyl, piperazinyl, tetrazolyl, or 3- to 8-membered cycloalkyl or 9- to 12-membered bicycloalkyl, optionally containing one to three of O, S or N—Z wherein Z is hydrogen, C1-C4 alkyl, C1-C4 alkanoyl, phenyl or phenylmethyl, wherein each one of the above groups may be substituted independently by from one to four of fluoro, chloro, C1-C6 alkyl, C1-C6 alkoxy or trifluoromethyl, or one of bromo, iodo, cyano, nitro, amino, NH(C1-C4 alkyl), N(C1-C4)(C1-C2 alkyl), COO(C1-C4 alkyl), CO(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), SO2NH2, NHSO2(C1-C4 alkyl), S(C1-C6 alkyl), SO2(C1-C6 alkyl), wherein said C1-C4 alkyl and C1-C6 alkyl may be substituted by one or two of fluoro, chloro, hydroxy, amino, methylamino, dimethylamino or acetyl; with the proviso that R5 is not unsubstituted phenyl;
  • R[0040] 11 is hydrogen, hydroxy, fluoro, chloro, COO(C1-C2 alkyl), cyano, or CO(C1-C2 alkyl); and
  • R[0041] 12 is hydrogen or C1-C4 alkyl; with the proviso that (1) when R5 is 4-bromophenyl, R3 is hydrogen, and R4 and R6 are methyl, then B is not methylamino or ethyl, and (2) when R5 is 4-bromophenyl, and R3, R4 and R6 are methyl, then B is not 2-hydroxyethylamino.
  • Ill. It is also possible to employ a CRF antagonist that has a structure selected from the group shown below, and pharmaceutically acceptable salts and esters thereof, as described in WO 95/33750: [0042]
    Figure US20020156089A1-20021024-C00003
  • wherein [0043]
  • A is CR[0044] 7 or N;
  • B is NR[0045] 1R2, CR1R2R11, C(═CR2R12)R1, NHCHR1R2, OCHR1R2, SCHR1R2, CHR2OR12, CHR2SR12, C(S)R2 or C(O)R2;
  • Y is CH or N; [0046]
  • Z is NH, O, S, N (C[0047] 1-C2 alkyl), or CR13R14, wherein R13 and R14 are each independently hydrogen, trifluoromethyl, or C1-C4 alkyl, or one of R13 and R14 may be cyano, chloro, bromo, iodo, fluoro, hydroxy, O(C1-C2 alkyl), amino, NH(C1-C2 alkyl), or CR13R14 may be C═O or cyclopropyl;
  • R[0048] 1 is C1-C6 alkyl which may be substituted by one or two substituents R8 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, O—CO-(C1-C4 alkyl), O—CO—NH(C1-C4 alkyl), O—CO—N(C1-C4 alkyl)(C1-C2 alkyl), NH(C1-C4 alkyl), N(C1-C2 alkyl)(C1-C4 alkyl), S(C1-C4 alkyl), N(C1-C4alkyl)CO(C1-C4 alkyl), NHCO(C1-C4 alkyl), COO(C1-C4 alkyl), CONH(C1-C4 alkyl), CON(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C4 alkyl), CN, NO2, SO(C1-C4 alkyl), SO2(C1-C4 alkyl), and said C1-C6 alkyl or C1-C4 alkyl may contain one double or triple bond;
  • R[0049] 2 is C1-C12 alkyl, aryl or (C1-C4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or (C1-C6 alkylene)cycloalkyl, wherein said cycloalkyl may contain one or two of O, S or N—R9 wherein R9 is hydrogen, or C1-C4 alkyl, wherein the above defined R2 may be substituted independently by from one to three of chloro, fluoro, or C1-C4 alkyl, or one of bromo, iodo, C1-C6 alkoxy, O—CO-(C1-C6 alkyl), O—CO—N(C1-C4 alkyl)(C1-C2 alkyl), S(C1-C6 alkyl), CN, NO2, SO(C1-C4 alkyl), or SO2(C1-C4 alkyl), an wherein said C1-C12 alkyl or C1-C4 alkylene may contain one double or triple bond; or
  • NR[0050] 1R2 or CR1R2R11 may form a saturated 5- to 8-membered carbocyclic ring which may contain one or two double bonds or one or two of O or S;
  • R[0051] 3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF3, methylthio, methylsulfonyl, CH2OH or CH2OCH3;
  • R[0052] 4 is hydrogen, C1-C4 alkyl, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, amino, nitro, NH(C1-C4 alkyl), N(C1-C4 alkyl)(C1-C2 alkyl), SOn(C1-C4 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, CO(C1-C4 alkyl), CHO, or COO(C1-C4 alkyl), wherein said C1-C4 alkyl may contain one or two double or triple bonds and may be substituted by one or two of hydroxy, amino, carboxy, NHCOCH3, NH(C1-C2 alkyl), N(C1-C2 alkyl)2, COO(C1-C4 alkyl), CO(C1-C4 alkyl), C1-C3 alkoxy, C1-C3 thioalkyl, fluoro, chloro, cyano or nitro;
  • R[0053] 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each one of the above groups R5 is substituted independently by from one to three of fluoro, chloro, C1-C6 alkyl, or C1-C6 alkoxy, or one of hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, NH(C1-C4 alkyl), N(C1-C6)(C1-C2 alkyl), COOH, COO(C1-C4 alkyl), CO(C1-C4 alkyl), SO2NH(C1-C4 alkyl), SO2N(C1-C4 alkyl)(C1-C2 alkyl), SO2NH2, NHSO2(C1-C4 alkyl), S(C1-C6 alkyl), or SO2(C1-C6 alkyl), wherein said C1-C4 alkyl and C1-C6 alkyl may be substituted by one or two of fluoro, hydroxy, amino, methylamino, dimethylamino or acetyl;
  • R[0054] 6 is hydrogen, or C1-C6 alkyl, wherein said C1-C6 alkyl may be substituted by one hydroxy, methoxy, ethoxy or fluoro;
  • R[0055] 7 is hydrogen, C1-C4 alkyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, O(C1-C4 alkyl), C(O)(C1-C4 alkyl), or C(O)O(C1-C4 alkyl), wherein the C1-C4 alkyl groups may be substituted with one hydroxy, chloro or bromo, or one to three fluoro;
  • R[0056] 11 is hydrogen, hydroxy, fluoro, or methoxy;
  • R[0057] 12 is hydrogen or C1-C4 alkyl; and
  • R[0058] 16 and R17 are each independently hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that they are not both methoxy or ethoxy, and CR4Rb 6 and CR16R17 each independently may be C═O.
  • IV. It also possible to employ a CRF antagonist of the following formula, disclosed in WO 95/34563: [0059]
    Figure US20020156089A1-20021024-C00004
  • and the pharmaceutically acceptable acid addition salts thereof, wherein [0060]
  • A is N or —CR[0061] 6;
  • B is —NR[0062] 1R2, —CR1R2R11, —C(═CR2R12)R1, —NHCHR1R2, —OCHR1R2, —SCHR1R2, —CHR2OR12, —CHR2SR12, —C(S)R1 or —C(O)R1;
  • R[0063] 1 is C1-C6 alkyl which may optionally be substituted with one or two substituents independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, —O—CO-(C1-C4 alkyl), —O—CO—NH(C1-C4 alkyl), —O—CO—N(C1-C4 alkyl)(C1-C2 alkyl), —NH(C1-C4 alkyl), —N(C1-C2 alkyl)(C1-C4 alkyl), —S(C1-C4 alkyl), —N(C1-C4alkyl)CO(C1-C4 alkyl), —NHCO(C1-C4 alkyl), —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), CN, NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), and wherein any of the foregoing C1-C4 alkyl and C1-C6 alkyl groups may optionally contain one carbon-carbon double or triple bond;
  • R[0064] 2 is C1-C12 alkyl, aryl, -(C1-C4 alkylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, thiazolyl, isoxazolyl, benzisoxazolyl, benzimidazolyl, triazolyl, pyrazolyl, pyrrolyl, indolyl, oxazolyl, or benzoxazolyl; or 3- to 8-membered cycloalkyl or -(C1-C6 alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C1-C6 alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N—Z wherein Z is hydrogen; or C1-C4 alkyl, and wherein each of said groups R2 may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C1-C4 alkyl, or by one substituent selected from bromo, iodo, C1-C6 alkoxy, —O—CO-(C1-C 6 alkyl), —S(C1-C6 alkyl), —COO(C1-C4 alkyl), CN, NO2, —SO(C1-C4 alkyl), and —SO2(C1-C4 alkyl), and wherein said C1-C12 alkyl and the C1-C4 alkylene moiety of said -(C1-C4 alkylene)aryl may optionally contain one carbon-carbon double or triple bond;
  • or —NR[0065] 1R2 may form a saturated 5- to 8-membered heterocyclic ring, or —CHR1R2 may form a saturated 5- to 8-membered carbocyclic ring, wherein each of these rings may optionally contain one or two carbon-carbon double bonds and wherein one or two of the carbon atoms of each of these rings may optionally be replaced with a sulfur or oxygen atom;
  • R[0066] 3 is C1-C4 alkyl, fluoro, chloro, bromo, iodo, —CH2OH, —CH2OCH3, —O(C1-C3 alkyl), —S(C1-C3 alkyl), or —SO2(C1-C3 alkyl), wherein said C1-C3 alkyl may optionally contain one carbon-carbon double or triple bond;
  • R[0067] 4 is hydrogen, C1-C6 alkyl, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, amino, —NHCH3, —N(CH3)2, —CH2OH, —CH2OCH3, or —SOn(C1-C4 alkyl), wherein n is 0, 1 or 2, cyano, hydroxy, —CO(C1-C4 alkyl), —CHO, or —COO(C1-C4 alkyl) wherein the C1-C4 alkyl moieties in the foregoing R4 groups may optionally contain one carbon-carbon double or triple bond;
  • R[0068] 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, pyrimidyl, benzofuranyl, pyrazinyl or benzothiazolyl, wherein each one of said groups R5 may optionally be substituted with from one to three substituents independently selected from fluoro, chloro, C1-C6 alkyl and C1-C6 alkoxy, or by one substituent selected from iodo, hydroxy, bromo, formyl, cyano, nitro, amino, trifluoromethyl, —NH(C1-C4 alkyl), —N(C1-C6)(C1-C2 alkyl), —COO(C1-C4 alkyl), —CO(C1-C4 alkyl), —COOH, —SO2NH(C1-C4 alkyl), —SO2N(C1-C4 alkyl)(C1-C2 alkyl), —SO2NH2, —NHSO2(C1-C4 alkyl), —S(C1-C6 alkyl) and —SO2(C1-C6 alkyl), wherein each of said C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally be substituted with one to three fluorine atoms;
  • R[0069] 6 is hydrogen, C1-C4 alkyl, fluoro, chloro, bromo, iodo, —CH2OH, —CH2OCH3, or C1-C4 alkoxy;
  • R[0070] 7 is hydrogen, C1-C4 alkyl, fluoro, chloro, bromo, iodo, —O(C1-C4 alkyl), cyano, —CH2OH, —CH2O(C1-C2 alkyl), —CO(C1-C2 alkyl), or —COO(C1-C2 alkyl);
  • R[0071] 11 is hydrogen, hydroxy, fluoro, or methoxy; and
  • R[0072] 12 is hydrogen or C1-C4 alkyl;
  • with the proviso that when A is N, then: (a) B is not unsubstituted alkyl; (b) R[0073] 5 is not unsubstituted phenyl or monosubstituted phenyl; and (c) R3 is not unsubstituted alkyl;
  • or a pharmaceutically acceptable salt of such compound. [0074]
  • V. In another embodiment, the CRF antagonist is of the following formula, disclosed in EP 778277: [0075]
    Figure US20020156089A1-20021024-C00005
  • or a pharmaceutically acceptable salt thereof, wherein [0076]
  • the dashed lines represent optional double bonds; [0077]
  • A is nitrogen or CR[0078] 7;
  • B is —NR[0079] 1R2, —CR1R2R10, —C(═CR2R11)R1, —NHCR1R2R10, —OCR1R2R10, —SCR1R2R10, —CR2R10NHR1, —CR2R10OR1, —CR2R10SR1 or —COR2;
  • D is nitrogen and is single bonded to all atoms to which it is attached, or D is carbon and is either double bonded to E in formulas I and II or double bonded to the adjacent carbon atom common to both fused rings in formula III, or D is CH and is single bonded to E in formulas I and II; [0080]
  • E is nitrogen, CH or carbon; [0081]
  • F is oxygen, sulfur, CHR[0082] 4 or NR4 when it is single bonded to E and F is nitrogen or CR4 when it is double bonded to E;
  • G, when single bonded to E, is hydrogen, C[0083] 1-C4 alkyl, —S(C1-C4 alkyl), —O(C1-C4 alkyl), NH2, —NH(C1-C4 alkyl) or —N(C1-C2 alkyl)(C1-C4 alkyl), wherein each of the C1-C4 alkyl groups of G may optionally be substituted with one hydroxy, —O(C1-C2 alkyl) or fluoro group; G, when double bonded to E, is oxygen, sulfur or NH; and G, when E is nitrogen and double bonded to D or F, is absent;
  • R[0084] 1 is hydrogen, C1-C6 alkyl optionally substituted with one or two substituents R8 independently selected from hydroxy, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, CF3, —C(═O)O-(C1 -C4)alkyl, —OC(═O)(C1-C4 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl), wherein each of the C1-C4 alkyl groups in the foregoing R1 groups may optionally contain one or two double or triple bonds;
  • R[0085] 2 is C1-C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1-C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C3-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1-C6 alkylene)(C3-C8 cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ2 wherein Z2 is selected from hydrogen, C1-C4 alkyl, benzyl and C1-C4 alkanoyl, and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from bromo, iodo, C1-C6 alkoxy, —OC(═O)(C1-C6 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C6 alkyl), amino, —NH(C1-C2 alkyl), —N(C1-C2 alkyl)(C1-C4 alkyl), —N(C1-C4 alkyl)-CO-(C1-C4 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —SH, —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl);
  • —NR[0086] 1R2 or CR1R2R10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ3 wherein Z3 is hydrogen, C1-C4 alkyl, benzyl or C1-C4 alkanoyl;
  • R[0087] 3 is hydrogen, C1-C4 alkyl, —O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, —CN, —S(C1-C4 alkyl) or —SO2(C1-C4 alkyl) wherein each of the (C1-C4 alkyl) moieties in the foregoing R3 groups may optionally be substituted with one substituent R9 selected from hydroxy, fluoro and (C1-C2 alkoxy);
  • each R[0088] 4 is, independently, hydrogen, (C1-C6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, nitro, —O(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —SO(C1-C4 alkyl), —SO2(C1-C4)alkyl, —CO(C1-C4 alkyl), —C(═O)H or —C(═O)O(C1-C4alkyl), wherein each of the (C1-C6 alkyl) and (C1-C4 alkyl) moieties in the foregoing R4 groups may optionally contain one or two double or triple bonds and may optionally be substituted with one or two substituents independently selected from hydroxy, amino, C1-C3 alkoxy, dimethylamino, methylamino, ethylamino, —NHC(═O)CH3, fluoro, chloro, C1-C3 thioalkyl, —CN, —COOH, —C(═O)O(C1-C4 alkyl), —C(═O)(C1-C4 alkyl) and —NO2;
  • R[0089] 5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, furanyl, benzofuranyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl or C3-C8 cycloalkyl wherein one or two of the carbon atoms of said cycloalkyl rings that contain at least 5 ring members may optionally and independently be replaced by an oxygen or sulfur atom or by NZ4 wherein Z4 is hydrogen, C1-C4 alkyl or benzyl; and wherein each of the foregoing R5 groups is substituted with from one to four substituents R12 wherein one to three of said substituents may be selected, independently, from chloro, C1-C6 alkyl and —O(C1-C6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, —CN, —CF3, —NO2, —NH2, —NH(C1-C4 alkyl), —N(C1-C2 alkyl)(C1-C6 alkyl), —C(═O)O(C1-C4 alkyl), —C(═O)(C1-C4 alkyl), —COOH, —SO2NH(C1-C4 alkyl), —SO2N(C1-C2 alkyl)(C1-C4 alkyl), —SO2NH2, —NHSO2(C1-C4 alkyl), —S(C1-C6 alkyl) and —SO2(C1-C6 alkyl), and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;
  • R[0090] 7 is hydrogen, C1-C4 alkyl, halo, cyano, hydroxy, —O(C1-C4 alkyl) —C(═O)(C1-C4 alkyl), —C(═O)O(C1-C4alkyl), —OCF3, —CF3, —CH2OH, —CH2O(C1-C4 alkyl);
  • R[0091] 10 is hydrogen, hydroxy, methoxy or fluoro;
  • R[0092] 11 is hydrogen or C1-C4 alkyl; and
  • Z is NH, oxygen, sulfur, —N(C[0093] 1-C4 alkyl), —NC(═O)(C1-C2 alkyl), NC(═O)O(C1-C2alkyl) or CR13R14 wherein R13 and R14 are independently selected from hydrogen, trifluoromethyl and methyl with the exception that one of R13 and R14can be cyano;
  • with the proviso that: (a) in the five membered rings of structures I, II and III, there can not be two double bonds adjacent to each other; and (b) when R[0094] 4 is attached to nitrogen, it is not halo, cyano or nitro;
  • or a pharmaceutically acceptable salt of such compound. [0095]
  • VI. The CRF antagonist can also be of the following formula, disclosed in WO 98/05661: [0096]
    Figure US20020156089A1-20021024-C00006
  • wherein the dashed lines represent optional double bonds; [0097]
  • A is nitrogen or CR[0098] 7;
  • B is —NR[0099] 1R2, —CR1R2R10, —C(═CR2R11)R1, —NHCR1R2R10, —OCR1R2R10, —SCR1R2R10, —CR2R10NHR1, —CR2R10OR1, —CR2R10SR1 or —COR2, and is single bonded to D; or B is —CR1R2, and is double bonded to D and D is carbon;
  • D is nitrogen or CR[0100] 4 and is single bonded to all atoms to which it is attached, or D is carbon and is double bonded to E or double bonded to B;
  • E is oxygen, nitrogen, sulfur, C═O, C═S, CR[0101] 6R12, NR6 or CR6; or E is a two atom spacer, wherein one of the atoms is oxygen, nitrogen, sulfur, C═O, C═S, CR6R12, NR6 or CR6, and the other is CR6R12 or CR9;
  • K and G are each, independently, C═O, C═S, sulfur, oxygen, CHR[0102] 6 or NR8 when single bonded to both adjacent ring atoms, or nitrogen or CR8 when it is double bonded to an adjacent ring atom;
  • the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C═O or C═S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring; [0103]
  • R[0104] 1 is C1-C6 alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, CF3, —C(═O)(C1-C4alkyl), —C(═O)—O-(C1-C4)alkyl, —OC(═O)(C1-C4 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl), wherein each of the C1-C4 alkyl groups in the foregoing r1 groups may optionally contain one or two double or triple bonds;
  • R[0105] 2 is C1-C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1-C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C1-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1-C6 alkylene)(C3-C8 cycloalkyl may optionally and independently be replaced by an oxygen or sulfur and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from C1-C6 alkoxy, —OC(═O)(C1-C6 alkyl), —OC(═O)N(C1-C4 alkyl)(C-C 2 alkyl), —S(C1-C6 alkyl), amino, —NH(C1C2 alkyl), —N(C1-C2 alkyl)(C1-C4 alkyl), —N(C1-C4 alkyl)-CO-(C1-C4 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —-CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —SH, —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl);
  • —NR[0106] 1R2 or CR1R2R10 may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ3 wherein Z3 is hydrogen or C1-C4 alkyl;
  • R[0107] 3 is hydrogen, C1-C4 alkyl, —O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, —S(C1-C4 alkyl) or —SO2(C1-C4 alkyl);
  • R[0108] 4 is hydrogen, C1-C2 alkyl, hydroxy or fluoro;
  • each R[0109] 6, R8 and R9 that is attached to a carbon atom is selected, independently, from hydrogen, C1-C2 alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxymethyl, formyl, trifluoromethyl, cyano, amino, nitro, —O(C1-C2 alkyl), —N(C1-C2 alkyl)(C1-C2 alkyl), —S(C1-C2 alkyl), —CO(C1-C2 alkyl), —C(═O)H or —C(═O)O(C1-C2 alkyl), wherein each of the C1-C2 alkyl moieties in the foregoing R6, R8, and R9 groups may optionally contain one double or triple bond; and each R6, R8, and R9 that is attached to a nitrogen atom is selected, independently, from hydrogen and C1-C4 alkyl;
  • R[0110] 5 is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R5 groups is substituted with from two to four substituents R15, wherein from one to three of said substituents may be selected, independently, from chloro, C1-C6 alkyl, —O(C1-C6 alkyl) and -(C1-C6alkylene)O(C1-C6alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, —NH(C1-C4 alkyl), —N(C1-C2 alkyl)(C1-C6 alkyl), —C(═O)O(C1-C4 alkyl), —C(═O)(C1-C4 alkyl), —COOH, —SO2NH(C1-C4 alkyl), —SO2N(C1-C2 alkyl)(C1-C4 alkyl), —SO2NH2, —NHSO2(C1-C4 alkyl), —S(C1-C6 alkyl) and —SO2(C1-C6 alkyl), and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;
  • R[0111] 7 is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, —C(═O)(C1-C2 alkyl), —C(═O)O(C1-C2 alkyl), trifluoromethoxy, hydroxymethyl, trifluoromethyl or formyl;
  • R[0112] 10 is hydrogen, hydroxy, methoxy or fluoro;
  • R[0113] 11 is hydrogen or C1-C4 alkyl;
  • R[0114] 12 is, hydrogen or methyl; and
  • Z is NH, oxygen, sulfur, —N(C[0115] 1-C4 alkyl), or CR13R14 wherein R13 and R14 are independently selected from hydrogen, and methyl with the exception that one of R13 and R14 may optionally be cyano;
  • with the proviso that: (a) in the six or seven membered rings of structures in formula I, there can not be two double bonds adjacent to each other; and (b) when D is carbon and is double bonded to B, then B is CR[0116] 1R2;
  • or a pharmaceutically acceptable salt of such compound. [0117]
  • VII. The CRF antagonist can also be of the following formula, disclosed in WO 98/08847: [0118]
    Figure US20020156089A1-20021024-C00007
  • or a pharmaceutically acceptable salt thereof, wherein [0119]
  • the dashed lines represent optional double bonds; [0120]
  • A is nitrogen or CR[0121] 7;
  • B is —NR[0122] 1R2, —CR1R2R10 —C(═CR2R11)R1, —NHCR1R2R10, —OCR1R2R10, —SCR1R2R10 , —CR2R10NHR1, —CR2R10OR1, —CR2R10SR1 or —COR2;
  • J and K are each independently nitrogen or carbon and both J and K are not nitrogens; [0123]
  • D and E are each selected, independently, from nitrogen, CR[0124] 4, C═O, C═S, sulfur, oxygen, CR4R6 and NR8;
  • G is nitrogen or carbon; [0125]
  • the ring containing D, E, G, K, and J in formula I may be a saturated or unsaturated 5-membered ring and may optionally contain one or two double bonds and may optionally contain from one to three heteroatoms in the ring and may optionally have one or two C═O or C═S groups; [0126]
  • R[0127] 1 is C1-C6 alkyl optionally substituted with one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, —O-(C1-C4 alkyl), CF3, —C(═O)O-(C1-C4alkyl), —OC(═O)(C1-C4 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C2 alkyl), wherein each of the C1-C4 alkyl groups in the foregoing R1 groups may optionally contain one or two double or triple bonds;
  • R[0128] 2 is C1-C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1-C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C1-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1-C6 alkylene)(C3-C8 cycloalkyl) may optionally and independently be replaced by an oxygen or sulfur atom or by NZ2 wherein Z2is selected from hydrogen, C1-C4 alkyl, benzyl and C1-C4 alkanoyl, and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from bromo, iodo, C1-C6 alkoxy, —OC(═O)(C1-C6 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C6 alkyl), amino, —NH(C1C2 alkyl), —N(C1-C2 alkyl)(C1-C4 alkyl), —N(C1-C4 alkyl)-CO-(C1-C4 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —SH, —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl);
  • —NR[0129] 1R2 or CR1R2R10 may form a saturated 3 to 8 membered carbocyclic ring which may optionally contain from one to three double bonds and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ3 wherein Z3 is hydrogen, C1-C4 alkyl, benzyl or C1-C4 alkanoyl;
  • R[0130] 3 is hydrogen, C1-C4 alkyl, —O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, (C1-C2 alkylene)-O-(C1-C2 alkyl), (C1-C2 alkylene)-OH, or —S(C1-C4 alkyl);
  • each R[0131] 4 is, independently, hydrogen, (C1-C6 alkyl), fluoro, chloro, bromo, iodo, hydroxy, cyano, amino, (C1-C2 alkylene)-OH, CF3, CH2SCH3, nitro, —O(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —CO(C1-C4 alkyl), —C(═O)H or —C(═O)O(C1-C4alkyl);
  • R[0132] 6 is hydrogen, methyl or ethyl;
  • R[0133] 8 is hydrogen or C1-C4 alkyl;
  • R[0134] 5 is phenyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl and wherein each of the foregoing R5 groups is substituted with from one to four substituents R13 wherein one to three of said substituents may be selected, independently, from fluoro, chloro, C1-C6 alkyl and —O(C1-C6 alkyl) and one of said substituents may be selected from bromo, iodo, formyl, OH, (C1-C4 alkylene)-OH, (C1-C4alkylene)-O-(C1-C2 alkyl), —CN, —CF3, —NO2, —NH2, —NH(C1-C4 alkyl), —N(C1-C2 alkyl)(C1-C6 alkyl), —OCO(C1-C4 alkyl), (C1-C4 alkylene)-O-(C1-C4 alkyl), —S(C1-C6 alkyl), (C1-C4 alkylene)-S-(C1-C4 alkyl), —C(═O)O(C1-C4 alkyl), —C(═O)(C1-C4 alkyl), —COOH, —SO2NH(C1-C4 alkyl), —SO2N(C1-C2 alkyl)(C1-C4 alkyl), —SO2NH2, —NHSO2(C1-C4 alkyl), —S(C1-C6 alkyl) and —SO2(C1-C6 alkyl), and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally have one or two double bonds;
  • R[0135] 7 is hydrogen, C1-C4 alkyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, —O(C1-C4 alkyl), -C(═O)(C1-C4 alkyl), —C(═O)O(C1-C4 alkyl), —OCF3, —CF3, —CH2OH or —CH2O(C1-C2 alkyl);
  • R[0136] 10 is hydrogen, hydroxy, methoxy or fluoro;
  • R[0137] 11 is hydrogen or C1-C4 alkyl; and
  • with the proviso that: a) when both J and K are carbons and D is CR[0138] 4 and E is nitrogen, then G can not be nitrogen; (b) when both J and K are carbons and D and G are nitrogens, then E can not be CR4 or C═O or C═S; (c) when both J and K are carbons and D and E are carbons, then G can not be nitrogen; (d) when G is carbon, it must be double banded to E; and (e) in the ring containing J, K, D, E and G, there can not be two double bonds adjacent to each other;
  • and the pharmaceutically acceptable salts of such compounds. [0139]
  • VII. Other useful CRF antagonists are of the following formula, disclosed in WO 98/08846: [0140]
    Figure US20020156089A1-20021024-C00008
  • wherein the dashed lines represent optional double bonds; [0141]
  • A is nitrogen or CR[0142] 7;
  • B is —NR[0143] 1R2, —CR1R2R2R10, —C(═CR2R11)R1, —NHCR1R2R10, —OCR1R2R10, —SCR1R2R10, —CR2R10NHR1, —CR2R10 OR1, —CR2R10SR1 or —COR2;
  • G is nitrogen or CR[0144] 4 and is single bonded to all atoms to which it is attached, or G is carbon and is double bonded to K;
  • K is nitrogen or CR[0145] 6 when double bonded to G or E, or K is oxygen, sulfur, C═O, C═S, CR6R2 or NR8 when single bonded to both adjacent ring atoms, or K is a two atom spacer, wherein one of the two ring atoms of the spacer is oxygen, nitrogen, sulfur, C═O, C═S, CR6R12, NR6 or CR6, and the other is CR6R12 or CR9 ;
  • D and E are each, independently, C═O, C═S, sulfur, oxygen, CR[0146] 4R6 or NR8 when single bonded to both adjacent ring atoms, or nitrogen or CR4 when it is double bonded to an adjacent ring atom;
  • the 6- or 7-membered ring that contains D, E, K and G may contain from one to three double bonds, from zero to two heteroatoms selected from oxygen, nitrogen and sulfur, and from zero to two C═O or C═S groups, wherein the carbon atoms of such groups are part of the ring and the oxygen and sulfur atoms are substituents on the ring; [0147]
  • R[0148] 1 is C1-C6 alkyl optionally substituted with from one or two substituents independently selected from hydroxy, fluoro, chloro, bromo, iodo, C1-C4 alkoxy, CF3, —C(═O)(C1-C4alkyl), —C(═O)—O-(C1-C4)alkyl, —OC(═O)(C1-C4 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C4 alkyl), —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl), wherein each of the C1-C4 alkyl groups in the foregoing R1 groups may optionally contain one or two double or triple bonds;
  • R[0149] 2 is C1-C12 alkyl which may optionally contain from one to three double or triple bonds, aryl or (C1-C4 alkylene)aryl, wherein said aryl and the aryl moiety of said (C1-C4 alkylene)aryl is selected from phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidinyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, pyrazolyl, pyrrolyl, indolyl, pyrrolopyridyl, oxazolyl and benzoxazolyl; C3-C8 cycloalkyl or (C1-C6 alkylene)(C3-C8 cycloalkyl), wherein one or two of the carbon atoms of said cycloalkyl and the 5 to 8 membered cycloalkyl moieties of said (C1-C6 alkylene)(C3-C8 cycloalkyl may optionally and independently be replaced by an oxygen or sulfur atom or by NZ wherein Z is hydrogen, C1-C4 alkyl or benzyl, and wherein each of the foregoing R2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, hydroxy and C1-C4 alkyl, or with one substituent selected from C1-C6 alkoxy, —OC(═O)(C1-C6 alkyl), —OC(═O)N(C1-C4 alkyl)(C1-C2 alkyl), —S(C1-C6 alkyl), amino, —NH(C1-C2 alkyl), —N(C1-C2 alkyl)(C1-C4 alkyl), —N(C1-C4 alkyl)-CO-(C1-C4 alkyl), —NHCO(C1-C4 alkyl), —COOH, —COO(C1-C4 alkyl), —CONH(C1-C4 alkyl), —CON(C1-C4 alkyl)(C1-C2 alkyl), —SH, —CN, —NO2, —SO(C1-C4 alkyl), —SO2(C1-C4 alkyl), —SO2NH(C1-C4 alkyl) and —SO2N(C1-C4 alkyl)(C1-C2 alkyl);
  • —NR[0150] 1R2 or CR1R2R10 may form a ring selected from saturated 3 to 8 membered rings, the 5 to 8 membered rings of which may optionally contain one or two double bonds, and wherein one or two of the ring carbon atoms of such 5 to 8 membered rings may optionally and independently be replaced by an oxygen or sulfur atom or by NZ2 wherein Z2 is hydrogen, benzyl or C1-C4 alkyl;
  • R[0151] 3 is hydrogen, C1-C4 alkyl, —O(C1-C4 alkyl), chloro, fluoro, bromo, iodo, —S(C1-C4 alkyl) or —SO2(C1-C4 alkyl);
  • each R[0152] 8, R9 and R12 is selected, independently, from hydrogen and C1-C2 alkyl;
  • each R[0153] 4 and R6 that is attached to a carbon atom is selected, independently, from hydrogen and C1-C6 alkyl, fluoro, chloro, bromo, iodo, hydroxy, hydroxy (C1-C2 alkyl), trifluoromethyl, cyano, amino, nitro, —O(C1-C4 alkyl), —N(C1-C4 alkyl)(C1-C2 alkyl), —CH2SCH3, —S(C1-C4 alkyl), —CO(C1-C4 alkyl), —C(═O)H or —C(═O)O(C1-C4 alkyl), wherein each of the C1-C2 alkyl moieties in the foregoing R4 and R6 groups may optionally contain one double or triple bond; and R6, when attached to a nitrogen atom, is selected from hydrogen and C1-C4 alkyl;
  • R[0154] 5 is substituted phenyl, naphthyl, pyridyl or pyrimidyl, wherein each of the foregoing R5 groups is substituted with from two to four substituents R13, wherein up to three of said substituents may be selected, independently, from chloro, C1-C6 alkyl, —O(C1-C6 alkyl) and -(C1-C6 alkylene)O(C1-C6alkyl), and wherein one of said substituents may be selected, independently, from bromo, iodo, formyl, cyano, trifluoromethyl, nitro, amino, —NH(C1-C4 alkyl), —N(C1-C2 alkyl)(C1-C6 alkyl), —C(═O)O(C1-C4 alkyl), —C(═O)(C1-C4 alkyl), —COOH, —SO2NH(C1-C4 alkyl), —SO2N(C1-C2 alkyl)(C1-C4 alkyl), —SO2NH2, —NHSO2(C1-C4 alkyl), -(C0-C1alkylene)-S-(C1-C2alkyl), -(C0-C1alkylene)-SO-(C1-C2alkyl), -(C0-C1alkylene) -SO2-(C1-C2alkyl) and -(C1-C4alkylene)-OH, and wherein each of the C1-C4 alkyl and C1-C6 alkyl moieties in the foregoing R5 groups may optionally be substituted with one or two substituents independently selected from fluoro, hydroxy, amino, methylamino, dimethylamino and acetyl;
  • R[0155] 7 is hydrogen, methyl, halo (e.g., chloro, fluoro, iodo or bromo), hydroxy, methoxy, —C(═O)(C1-C2 alkyl), —C(═O)O(C1-C2 alkyl), hydroxymethyl, trifluoromethyl or formyl;
  • R[0156] 10 is hydrogen, hydroxy, methoxy or fluoro; and
  • R[0157] 11 is hydrogen or C1-C4 alkyl;
  • with the proviso that in the ring containing D, E, K and G of formula I, there can not be two double bonds adjacent to each other; [0158]
  • and the pharmaceutically acceptable salt of such compound. [0159]
  • IX. The CRF antagonist may also be of the following formula, disclosed in WO 95/10506: [0160]
    Figure US20020156089A1-20021024-C00009
  • or a pharmaceutically, acceptable salt or prodrug thereof, wherein Y is CR[0161] 3a, N, or CR29;
  • when Y is CR[0162] 3a or N:
  • R[0163] 1 is independently selected at each occurrence from the group consisting of C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, halogen, C1-C2 haloalkyl, NR6R7, OR8, and S(O)nR8; R3 is C1-C4 alkyl, aryl, C3-C6 cycloalkyl, C1-C2 haloalkyl, halogen, nitro, NR6R7, OR8, S(O)nR8 C(═O)R9, C(═O)NR6R7, C(═S)NR6R7, -(CHR16)kNR6R7, (CH2)kOR8, C(═O)NR10CH(R11)CO2R12, —C(OH)(R25)(R25a), -(CH2)pS(O)n-alkyl, —(CHR16)R25, —C(CN)(R25)(R16) provided that R25 is not —NH— containing rings, —C(═O)R25, —CH(CO2R16)2, NR10C(═O)CH(R11)NR10R12, NR10CH(R11)CO2R12; substituted C1-C4 alkyl, substituted C2-C4 alkenyl, substituted C2-C4 alkynyl, substituted C1-C4 alkoxy, aryl-(substituted C1-C4) alkyl, aryl-(substituted C1-C4) alkoxy, substituted C3-C6 cycloalkyl, amino-(substituted C1-C4)alkyl, substituted C1-C4 alkylamino, where substitution by R27 can occur on any carbon containing substituent; 2-pyridinyl, imidazolyl, 3-pyridinyl, 4-pyridinyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 4-pyrazinyl, azetidinyl, phenyl, 1H-indazolyl, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazolyl, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, azepinyl, benzofuranyl, benzothiophenyl, carbazolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, furazanyl, imidazolidinyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, benzimidazolyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxazolidinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, β-carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, tetrazolyl, thianthrenyl, thiazolyl, thiophenyl, triazinyl, xanthenyl; or 1-tetrahydroquinolinyl or 2-tetrahydroisoquinolinyl either of which can be substituted with 0-3 groups chosen from keto and C1-C4 alkyl; J, K, and L are independently selected at each occurrence from the group of N, CH, and CX′;
  • M is CR[0164] 5 or N;
  • V is CR[0165] 1a or N;
  • Z is CR[0166] 2 or N;
  • R[0167] 1a, R2, and R3a are independently selected at each occurrence from the group consisting of hydrogen, halo, halomethyl, C1-C3 alkyl, and cyano;
  • R[0168] 4 is (CH2)mOR16, C1-C4 alkyl, allyl, propargyl, (CH2)mR13, or —(CH2)mOC(O)R16;
  • X is halogen, aryl, heteroaryl, S(O)[0169] 2R8, SR8, halomethyl, —(CH2)pOR8, cyano, —(CHR16)pNR14R15, —C(═O)R8, C1-C6 alkyl, C4-C10 cycloalkylalkyl, C1-C10alkenyl, C1-C10alkynyl, C2-C10alkoxy, aryl-(C2-C10)-alkyl, C3-C6cycloalkyl, aryl-(C1-C10)-alkoxy, nitro, thio-(C1-C10)-alkyl, —C(═NOR16)-C1-C4-alkyl, —C(═NOR16)H, or —C(═O)NR14R15, where substitution by R18 can occur on any carbon containing substituents;
  • X′ is independently selected at each occurrence from the group consisting of hydrogen, halogen, aryl, heteroaryl, S(O)[0170] nR8, halomethyl, —(CHR16)pOR8, cyano, —(CHR16)pNR14R15, C(═O)R8, C1-C6 alkyl, C2-C10alkenyl, Cc-C10alkynyl, C1-C10alkoxy, aryl-(C1-C1)-alkyl, C3-C6cycloalkyl, aryl-(C1-C10)-alkoxy, nitro, thio-(C1-C10)-alkyl, —C(═NOR16)-C1C4-alkyl, —C(═NOR16)H, and —C(═O)NR14R15, where substitution by R16 can occur on any carbon containing substituents;
  • R[0171] 5 is halo, —C(═NOR16)-C1-C4-alkyl, C1-C4alkyl, C1-C3 haloalkyl, —(CHR16)pOR8, —(CHR16)pS(O),R8, —(CHR6)pNR14R15, C3-C6 cycloalkyl, C2-C10alkenyl, C2-C10alkynyl, aryl-(C2-C10)-akyl, aryl-(C1-C10)-alkoxy, cyano, C3-C6 cycloalkoxy, nitro, amino- (C2-C10)-alkyl, thio-(C2-C10)-alkyl, SOn(R8), C(═O)R8 -C(═NOR16)H, or —C(═O)NR14R15, where substitution by R18 can occur on any carbon containing substituents;
  • R[0172] 6 and R7 are independently selected at each occurrence from the group consisting of hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C6 alkoxy, (C4-C12)-cycloalkylalkyl, —(CH2)kR13, (CHR16)pOR8, -(C1-C6alkyl)-aryl, heteroaryl, —S(O)z-aryl or -(C1-C6alkyl)-heteroaryl or aryl, wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, amino, NHC(═O)(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C6 alkyl)2, nitro, carboxy, CO2(C1-C6 alkyl), cyano, and S(O)2-(C1-C6-alkyl); or can be taken together to form —(CH2)pA(CH2)r—, optionally substituted with 0-3 R17 or, when considered with the commonly attached nitrogen, can be taken together to form a heterocycle, said heterocycle being substituted on carbon with 1-3 groups consisting of hydrogen, C1-C6 alkyl, hydroxy, or C1-C6 alkoxy;
  • A is CH[0173] 2, O, NR25 C(═O), S(O)n, N(C(═O)R17), N(R19), C(H)(NR14R15) C(H)(OR20), C(H)(C(═O)R21), or N(S(O)nR21);
  • R[0174] 8 is independently selected at each occurrence from the group consisting of hydrogen; C1-C6 alkyl; -(C4-C12) cycloalkylalkyl; (CH2)tR22; C3-C10 cycloalkyl; —NR6R7; aryl; heteroaryl; —NR16(CH2)nR6R7; —(CH2)kR25; and (CH2)theteroaryl or (CH2)taryl, either of which can optionally be substituted with 1-3 groups selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, amino, NHC(═O)(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C6 alkyl)2, nitro, carboxy, CO2(C1-C6 alkyl), cyano, and S(O)2(C1-C6-alkyl);
  • R[0175] 9 is independently selected at each occurrence from R10, hydroxy, C1-C4 alkoxy, C3-C6 cycloalkyl, C2-C4 alkenyl, aryl substituted with 0-3 R18, and -(C1-C6 alkyl)-aryl substituted with 0-3 R18;
  • R[0176] 10, R16, R24, and R2 are independently selected at each occurrence from hydrogen or C1-C4 alkyl;
  • R[0177] 11 is C1-C4 alkyl substituted with 0-3 groups chosen from the following: keto, amino, sulfhydryl, hydroxyl, guanidinyl, p-hydroxyphenyl, imidazolyl, phenyl, indolyl, and indolinyl, or, when taken together with an adjacent R10, are (CH2)t;
  • R[0178] 12 is hydrogen or an appropriate amine protecting group for nitrogen or an appropriate carboxylic acid protecting group for carboxyl;
  • R[0179] 13 is independently selected at each occurrence from the group consisting of CN, OR19, SR19, and C3-C6 cycloalkyl;
  • R[0180] 14 and R15 are independently selected at each occurrence from the group consisting of hydrogen, C4-C10, cycloalkyl-alkyl, and R19;
  • R[0181] 17 is independently selected at each occurrence from the group consisting of R10, C1-C4 alkoxy, halo, OR23, SR23, NR23R24, and (C1-C6) alkyl (C1-C4) alkoxy;
  • R[0182] 18 is independently selected at each occurrence from the group consisting of R10, hydroxy, halogen, C1-C2 haloalkyl, C1-C4 alkoxy, C(═O)R24, and cyano;
  • R[0183] 19 is independently selected at each occurrence from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, (CH2)wR22, and aryl substituted with 0-3 R18;
  • R[0184] 20 is independently selected at each occurrence from the group consisting of R10, C(═O)R31, and C2-C4 alkenyl;
  • R[0185] 21 is independently selected at each occurrence from the group consisting of R10, C1-C4 alkoxy, NR23R24, and hydroxyl;
  • R[0186] 22 is independently selected at each occurrence from the group consisting of cyano, OR24, SR24, NR23R24, C1-C6 alkyl, C3-C6 cycloalkyl, —S(O)nR31, and —C(═O)R25;
  • R[0187] 25, which can be optionally substituted with 0-3 R17, is independently selected at each occurrence from the group consisting of phenyl, pyrazolyl, imidazolyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-pheno-thiazinyl, 4-pyrazinyl, azetidinyl, 1H-indazolyl, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl 4aH-carbazolyl, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, azepinyl, benzofuranyl, benzothiophenyl, carbazolyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, furazanyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl benzimidazolyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxazolidinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazolidinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, quinuclidinyl, B-carbolinyl, tetrahydrofuranyl, tetrazolyl, thianthrenyl, thiazolyl, thiophenyl, triazinyl, xanthenyl; and 1-tetrahydroquinolinyl or 2-tetrahydroisoquinolinyl either of which can be substituted with 0-3 groups chosen from keto and C1-C4 alkyl;
  • R[0188] 25a, which can be optionally substituted with 0-3 R17, is independently selected at each occurrence from the group consisting of H and R25;
  • R[0189] 27 is independently selected at each occurrence from the group consisting of C1-C3 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 alkoxy, aryl, nitro, cyano, halogen, aryloxy, and heterocycle optionally linked through 0;
  • R[0190] 31 is independently selected at each occurrence from the group consisting of C1-C4 alkyl, C3-C7 cycloalkyl, C4-C10 cycloalkyl-alkyl, and aryl-(C1-C4) alkyl;
  • k, m, and r are independently selected at each occurrence from 1-4; [0191]
  • n is independently, selected at each occurrence from 0-2, [0192]
  • p, q, and z are independently selected at each occurrence from 0-3; [0193]
  • t and w are independently selected at each occurrence from 1-6, [0194]
  • provided that when J is CX′ and K and L are both CH, and M is CR[0195] 5, then
  • (A) when V and Y are N and Z is CH and R[0196] 1 and R3 are methyl,
  • (1) and R[0197] 4 is methyl, then
  • (a) R[0198] 5 can not be methyl when X is OH and X′ is H;
  • (b) R[0199] 5 can not be —NHCH3, or —N(CH3)2 when X and X′ are—OCH3; and
  • (c) R[0200] 5 can not be —N(CH3)2 when X and X′ are —OCH2CH3;
  • (2) and R[0201] 4 is ethyl, then
  • (a) R[0202] 5 can not be methylamine when X and X′ are —OCH3;
  • (b) R[0203] 5 can not be OH when X is Br and X′ is OH; and
  • (c) R[0204] 5 can not be —CH2OH or —CH2N(CH3)2 when X is —SCH3 and X′is H;
  • (B) when V and Y are N, Z is CH, R[0205] 4 is ethyl, R5 is iso-propyl, X is Br, X′ is H, and
  • (1) R[0206] 1 is CH3, then
  • (a) R[0207] 3 can not be OH, piperazin-1-yl, —CH2,-piperidin-1-yl, —CH2-(N-4-methylpiperazin-1-yl), —C(O)NH-phenyl, —CO2H, —CH2O-(4-pyridyl), —C(O)NH2, 2-indolyl, —CH2O-(4-carboxyphenyl), —N(CH2CH3)(2-bromo-4-isopropylphenyl);
  • (2) R[0208] 2 is —CH2CH2CH3 then R3 can not be —CH2CH2CH3
  • (C) when V, Y and Z are N, R[0209] 4 is ethyl, and
  • (1) R[0210] 5 is iso-propyl, X is bromo, and X′ is H, then
  • (a) R[0211] 3 can not be OH or —OCH2CN when R1 is CH3 and
  • (b) R[0212] 3can not be —N(CH3)2 when R1 is —N(CH3)2;
  • (2) R[0213] 5 is —OCH3, X is —OCH3, and X′ is H, then R3 and R1 can not both be chloro; further provided that when J, K, and L are all CH and M is CR5, then
  • (D) at least one of V, Y, and Z must be N; [0214]
  • (E) when V is CR[0215] 1a, Z and Y can not both be N;
  • (F) when Y is CR[0216] 3a, Z and V can not both be N;
  • (G) when Z is CR[0217] 2, V and Y must both be N;
  • (H) Z can be N only when both V and Y are N or when V is CR[0218] 1a and Y is CR3a;
  • (I) when V and Y are N, Z is CR[0219] 2, and R2 is H or C1-C3 alkyl, and R4 is C1-C3 alkyl, R3 can not be 2-pyridinyl, indolyl, indolinyl, imidazolyl, 3-pyridinyl, 4-pyridinyl, 2-methyl-3-pyridinyl, 4-methyl-3-pyridinyl, furanyl, 5-methyl-2-furanyl, 2,5-dimethyl-3-furanyl, 2-thienyl, 3-thienyl, 5-methyl-2-thienyl, 2-phenothiazinyl, or 4-pyrazinyl;
  • (J) when V and Y are N; Z is CR[0220] 2; R is H or C1-C3 alkyl; R4 is C1-C4 alkyl, R5, X, and/or X′ are OH, halo, CF3, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio, cyano, amino, carbamoyl, or C1-C4 alkanoyl; and R1 is C1-C4 alkyl, then R4 can not be —NH(substituted phenyl) or —N(C1-C4 alkyl) (substituted phenyl);
  • and wherein, when Y is CR[0221] 29:
  • J, K, L, M, Z, A, k, m, n, p, q, r, t, w, R[0222] 3, R10, R11, R12, R13, R16, R18, R19, R21, R23, R24, R25, and R27 are as defined above and R25a, in addition to being as defined above, can also be C1-C4 alkyl, but
  • V is N; [0223]
  • R[0224] 1 is C1-C2 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C2-C4 alkoxy, halogen, amino, methylamino, dimethylamino, aminomethyl, or N-methylaminomethyl;
  • R[0225] 2 is independently selected at each occurrence from the group consisting of hydrogen, halo, C1-C3, alkyl, nitro, amino, and —CO2R10;
  • R[0226] 4 is taken together with R29 to form a 5-membered ring and is —C(R26)═ or —N═ when R29 is —C(R30)═ or —N═, or —CH(R26)— when R29 is —CH(R30)—;
  • X is Cl, Br, I, S(O)nR[0227] 8, OR8, halomethyl, —(CHR )pOR8, cyano, —(CHR16)pNR14R15, C(═O)R8, C1-C6 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10, alkoxy, aryl-(C1-C10)-alkyl, C3-C6 cycloalkyl, aryl-(C1-C10)-alkoxy, nitro, thio-(C1-C10)-alkyl, —C(═NOR16)-C1—C4-alkyl, —C(═NOR16)H, or C(═O)NR14R15 where substitution by R18 can occur on any carbon containing substituents;
  • X′ is hydrogen, Cl, Br, I, S(O)[0228] nR8, —(CHR16)pOR8, halomethyl, cyano, —(CHR16)pNR14R15, C(═O)R8, C1-C6 alkyl, C2-C10alkenyl, C1-C10 alkoxy, aryl-(C1-C10)-alkyl, C3-C6 cycloalkyl, aryl-(C2-C10)-alkoxy, nitro, thio-(C2-C10)-alkyl, —C(═NOR16)-C1-C4-alkyl, —C(═NOR16)H, or C(═O)NR8R15 where substitution by R18 can occur on any carbon containing substituents;
  • R[0229] 5 is halo, —C(═NOR16)-C1-C4-alkyl, C1-C6 alkyl, C1-C3 haloalkyl, C1-C6 alkoxy, (CHR16)pOR5, (CHR16)pS(O)nR8, (CHR16)pNR14R15, C3-C6 cycloalkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl-(C2-C10)-alkyl, aryl-(C1-C10)-alkoxy, cyano, C3-C6 cycloalkoxy, nitro, amino-(C1-C10)-alkyl, thio-(C1-C10)-alkyl, SOn(R8), C(═O)R8, —C(═NOR16)H, or C(═O)NR8R15 where substitution by R18 can occur on any carbon containing substituents;
  • R[0230] 6 and R7 are independently selected at each occurrence from the group consisting of hydrogen, C1-C6 alkyl, C3-C10 cycloalkyl, —(CH2)kR13, (C4-C12)-cycloalkylalkyl, C1-C6 alkoxy, -(C1-C6 alkyl)-aryl, heteroaryl, aryl, —S(O),-aryl or -(C1-C6 alkyl)-heteroaryl or aryl wherein the aryl or heteroaryl groups are optionally substituted with 1-3 groups selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, amino, NHC(═O)(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C6 alkyl)2, nitro, carboxy, CO2(C1-C6 alkyl), and cyano; or can be taken together to form —(CH2)qA(CH2)r—, optionally substituted with 0-3 R17; or, when considered with the commonly attached nitrogen, can be taken together to form a heterocycle, said heterocycle being substituted on carbon with 1-3 groups consisting of hydrogen, C1-C6 alkyl, hydroxy, or C1-C6 alkoxy;
  • R[0231] 8 is independently selected at each occurrence from the group consisting of hydrogen, C1-C6 alkyl, -(C4-C12) cycloalkylalkyl, (CH2)R22, C3-C10 cycloalkyl, -(C1-C6 alkyl)-aryl, heteroaryl, —NR16, —N(CH2)nNR6R7; —(CH2)kR25, -(C1-C6 alkyl)-heteroaryl or aryl optionally substituted with 1-3 groups selected from hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, amino, NHC(═O)(C1-C6 alkyl), NH(C1-C6 alkyl), N(C1-C6alkyl)2, nitro, carboxy, CO2(C1-C6 alkyl), and cyano;
  • R[0232] 9 is independently selected at each occurrence from R10, hydroxy, C1-C4 alkoxy, C3-C6 cycloalkyl, C2-C4 alkenyl, and aryl substituted with 0-3 R18;
  • R[0233] 14and R15 are independently selected at each occurrence from the group consisting of hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, (CH2)tR22, and aryl substituted with 0-3 R18;
  • R[0234] 17 is independently selected at each occurrence from the group consisting of R10, C1-C4 alkoxy, halo, OR23, SR23, and NR23R24;
  • R[0235] 20 is independently selected at each occurrence from the group consisting of R10 and C(═O)R31;
  • R[0236] 22 is independently selected at each occurrence from the group consisting of cyano, OR24, SR24, NR23R24, C3-C6 cycloalkyl, —S(O)nR31, and —C(═O)R25;
  • R[0237] 26 is hydrogen or halogen;
  • R[0238] 28 is C1-C2, alkyl, C2-C4 alkenyl, C2-C4 alkynyl, hydrogen, C1-C2 alkoxy, halogen, or C2-C4 alkylamino;
  • R[0239] 29 is taken together with R4 to form a five membered ring and is: —CH(R30)— when R4 is —CH(R28)—, —C(R30)═ or —N═ when R4 is —C(R28)═or —N═;
  • R[0240] 30 is hydrogen, cyano, C1-C2 alkyl, C1-C2 alkoxy, halogen, C1-C2 alkenyl, nitro, amido, carboxy, or amino;
  • R[0241] 31 is C1-C4 alkyl, C3-C7 cycloalkyl, or aryl-(C1-C4) alkyl; provided that when J, K, and L are all CH, M is CR5, Z is CH, R3 is CH3, R28 is H, R5 is isopropyl, X is Br, X′ is H, and R1 is CH3, then R30 can not be H, —CO2H, or —CH2NH2; and further provided that when J, K and L are all CH; M is CR5; Z is N; and
  • (A) R[0242] 29 is —C(R30)═; then one of R28 or R30 is hydrogen;
  • (B) R[0243] 29 is N; then R3 is not halo, NH2, NO2, CF3, CO2H, CO2-alkyl, alkyl, acyl, alkoxy, OH, or —(CH2)mOalkyl;
  • (C) R[0244] 29 is N; then R28 is not methyl if X or X′ are bromo or methyl and R5 is nitro; or
  • (D) R[0245] 29 is N; and R1 is CH3; and R3 is amino; then R5 is not halogen or methyl.
  • Preferred compounds of this group include those wherein: [0246]
  • i) V is N, R[0247] 1 is methyl; and R3 is aryl, NR6R7, or OR8;
  • ii) V is N, R[0248] 1 is methyl; R3 is aryl, NR6R7, or OR8; and R4 is methyl or ethyl;
  • iii) V is N, R[0249] 1 is methyl; R3 is aryl, NR6R7, or OR8; R4 is methyl or ethyl; and X is O(C1-C4 alkyl), Br, or C1-C4 alkyl;
  • iv) V is N, R[0250] 1 is methyl; R3 is aryl, NR6R7, or OR8; R4 is methyl, ethyl; X is OMe, Br, or (C1-C4 alkyl), M is C1-C4 alkyl, Br, Cl, or O(C1-C4 alkyl); and
  • v) V is N, R[0251] 1 is methyl; R3 is aryl, NR6R7, OR8; or R4 is methyl, ethyl; X is OMe, Br, or C1-C4 alkyl, M is C1-C4 alkyl, Br, Cl, or O(C1-C4 alkyl); and L is CH, or N.
  • X. The invention also encompasses use of aminothiazole derivatives of the following formula, disclosed in WO 97/00868: [0252]
    Figure US20020156089A1-20021024-C00010
  • wherein each of R[0253] 1 and R2 is independently a halogen atom; a C1-C5 hydroxyalkyl radical; C1-C5 alkyl; C7-C10 aralkyl; C1-C5 alkoxy; trifluoromethyl; nitro; nitrile; a group —SR where R is hydrogen, a C1-C5 alkyl radical or a C7-C10 aralkyl radical; a group S—CO—R where R is a C1-C5 alkyl radical or aralkyl in which the aryl portion is C6-C8 and the alkyl portion is C1-C4; a group —COOR′ where R′ is hydrogen or C1-C5 alkyl; a group —CONR′R″ where R′ and R″ are as defined above for R′; a group —NR′R″ where R′ and R″ are as previously defined for R′; a group —CONRaRb or NRaRb, where Ra and Rb, taken together with the nitrogen atom to which they are attached, form a 5- to 7-membered heterocyclic ring; or a group —NHCO— NR′R″, where R′ and R″ are as defined above for R′; R3 is hydrogen or as defined for R1 and R2 is a hydrogen atom; C1-5 alkyl; halogen; a hydroxymethyl group; or a formyl group; R5 is C1-C5 alkyl; a C3-C7 cycloalkyl group; a cycloalkylalkyl group in which the cycloalkyl portion is C3-C7 and the alkyl portion is C1-C5; or C5-C6 alkenyl; n is 0 or 1; R6 is C1-5 alkyl; alkoxyalkyl in which the alkyl portions are C1-C5; C3-C7 cycloalkyl; a cycloalkylalkyl group in which the cycloalkyl portion is C3-C7 and the alkyl portion is C1-C5; a cycloalkyloxyalkyl radical in which the cycloalkyl is C3-C7 and the alkyl is C1-C4; a hydroxyalkyloxyalkyl radical in which the alkyls are C2-C10; or an alkoxyalkyloxyalkyl radical in which the alkyls are C3-C12; and Z is an optionally substituted bi- or tricyclic aromatic or heteroaromatic group; and stereoisomers and/or addition salts thereof.
  • XI. CRF antagonists of the following formula, disclosed in WO 97/29109, may also be employed: [0254]
    Figure US20020156089A1-20021024-C00011
  • including the stereoisomers and the pharmaceutically acceptable acid addition salt [0255]
  • forms thereof, wherein [0256]
  • R[0257] 1 is NR4R5 or OR5;
  • R[0258] 2 is C1-C6alkyl, C1-C6alkyloxy or C1-C6alkylthio,
  • R[0259] 3 is hydrogen, C1-C6alkyl, C1-C6alkylsulfonyl, C1-C6alkylsulfoxy or C1-C6alkylthio;
  • R[0260] 4 is hydrogen, C1-C6alkyl, mono- or di(C3-C6cyloalkylmethyl, C3-C6cyloalkyl, C3-C6alkenyl, hydroxyC1-C6alkyl, C1-C6akylcarbonyloxyC1-C6alkyl or C1-C6alkyloxyC1-C6alkyl;
  • R[0261] 5 is C1-C8alkyl, mono- or di(C3-C6cycloalkyl)methyl, Ar1CH2, C3-C6alkenyl, C1-C6alkyloxyC1-C6alkyl, hydroxyC1-C6alkyl, thienylmethyl, furanylmethyl, C1-C6alkylthioC1-C6alkyl, morpholinyl, mono- or di(C1-C6alkyl)aminoC1-6alkyl, di(C1-C6alkyl)amino, C1-C6alkylcarbonylC1-C6alkyl, C1-C6alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar1;
  • or R[0262] 4 and R5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-C6alkyl or C1-C6alkyloxyC1-C6alkyl; and
  • Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C[0263] 1-C6alkyl, trifluoromethyl, hydroxy, cyano, C1-C6alkyloxy, benzyloxy, C1-C6alkylthio, nitro, amino and mono- or di(C1-C6alkyl)amino; pyridinyl; pyridinyl substituted with I˜2 or 3 substituents independently selected from halo, C1-C6alkyl, trifluoromethyl, hydroxy, cyano, C1-C6alkyloxy, benzyloxy, C1-C6alkylthio, nitro, amino, mono- or di(C1-C6alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;
  • Ar[0264] 1 is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6alkyl, C1-C6alkyloxy, di(C1-C6alkyl)aminoC1-C6alkyl, trifluoromethyl and C1-C6alkyl substituted with morpholinyl; or pyridinyl; and Alk is C1-C6alkanediyl; with the proviso that 5-methyl-3-phenyl-7-(phenylmethoxy)-pyrazolo[1,5-a]-pyrimidine and 2,5-dimethyl-7-(methylamino)-3-phenyl-pyrazolo[1,5-a]pyrimidine are not included.
  • Preferred compounds of this formula are those wherein R[0265] 2 is methyl; R3 is hydrogen, or C1-C6 alkyl; and Ar is substituted phenyl or 3-pyridyl.
  • XII. CRF antagonists of the following formula, disclosed in WO 97/29110, may also be employed: [0266]
    Figure US20020156089A1-20021024-C00012
  • including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein [0267]
  • X is S. SO or SO[0268] 2;
  • R[0269] 1 is NR4R5 or OR5;
  • R[0270] 2 is C1-C6alkyl, C1-C6alkyloxy or C1-C6alkylthio;
  • R[0271] 3 is hydrogen, C1-C6alkyl, C1-C6alkylsulfonyl, C1-C6alkylsulfoxy or C1-C6alkylthio;
  • R[0272] 4 is hydrogen, C1-6alkyl, mono- or di(C3-C6cycloalkyl)methyl, C3-C6cycloalkyl, C3-C6alkenyl, hydroxyC1-C6alkyl, C1-C6alkylcarbonyloxyC1-C6alkyl or C1-C6alkyloxyC1-C6alkyl;
  • R[0273] 5 is C1-C8alkyl, mono- or di(C3-C6cycloalkyl)methyl, Ar1CH2, C3-C6alkenyl, C1-C6alkyloxyC1-C6alkyl, hydroxyC1-C6alkyl, thienylmethyl, furanylmethyl, C1-C6alkylthioC1-C6alkyl, morpholinyl, mono- or di(C1-C6alkyl)aminoC1-C6alkyl, di(C1-C6alkyl)amino, C1-C6alkylcarbonylC1-C6alkyl, C1-C6alkyl substituted with imidazolyl; or a radical of formula —Alk—O—CO—Ar I; or R4 and R5 taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C1-C6alkyl or C1-C6alkyloxyC1-C6alkyl;
  • Ar is phenyl; phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C[0274] 1-C6alkyl, trifluoromethyl, hydroxy, cyano, C1-C6alkyloxy, benzyloxy, C1-C6alkylthio, nitro, amino and mono- or di(C1-C6alkyl)amino; pyridinyl; pyridinyl substituted with 1, 2 or 3 substituents independently selected from halo, C1-C6alkyl, trifluoromethyl, hydroxy, cyano, C1-C6alkyloxy, benzyloxy, C1-C6alkylthio, nitro, amino, mono- or di(C1-C6alkyl)amino and piperidinyl; and wherein said substituted phenyl may optionally be further substituted with one or more halogens;
  • Ar[0275] 1is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, C1-C6alkyl, C1-C6alkyloxy, di(C1-C6alkyl)aminoC1-C6alkyl trifluoromethyl, and C1-C6alkyl substituted with morpholinyl; or pyridinyl; and
  • Alk is C[0276] 1-C6alkanediyl.
  • Preferred compounds of this group include those wherein: [0277]
  • i) R[0278] 2 is methyl;
  • ii) R[0279] 2 is methyl; and Ar is substituted phenyl or 3-pyridyl;
  • iii) R[0280] 2 is methyl; R3 is methyl; and Ar is substituted phenyl or 3-pyridyl.
  • Specific CRF antagonists useful in the practice of the invention, include, without limitation, the following compounds: [0281]
  • 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine; [0282]
  • butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethyl-amino; [0283]
  • 4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one; [0284]
  • 4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine; [0285]
  • N-butyl-N-ethyl-2,5-dimethyl-NN-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine; [0286]
  • [4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine; [0287]
  • 6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one; [0288]
  • 3-{(4-methyl-benzyl)-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-propan-1-ol; [0289]
  • diethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0290]
  • 2-{butyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-ethanol; [0291]
  • dibutyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-amine; [0292]
  • butyl-ethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0293]
  • butyl-ethyl-(6-methyl-3-methylsulfonyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0294]
  • butyl-cyclopropylmethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0295]
  • di-1-propyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0296]
  • diallyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0297]
  • butyl-ethyl-[6-chloro-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0298]
  • butyl-ethyl-[6-methoxy-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0299]
  • propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine; [0300]
  • 4-(1-ethyl-propyl)-6-methyl-3-methylsulfanyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine; [0301]
  • n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0302]
  • di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0303]
  • ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0304]
  • diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0305]
  • n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0306]
  • 2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol; [0307]
  • 4-(1 -ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine; [0308]
  • n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine; [0309]
  • 2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl]-(1-ethyl-propyl) amine; [0310]
  • butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyridin-4-yl]-ethylamine; [0311]
  • [3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine; [0312]
  • 4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine; [0313]
  • (1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine; [0314]
  • 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine; [0315]
  • 4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine; [0316]
  • 4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,6-dimethyl-4-bromophenyl)-7H-pyrrolo[2,3-b]pyridine; [0317]
  • 2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine; [0318]
  • 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one; [0319]
  • 9-(1-ethylpropyl)-2-methyl-6-(2,4,6-trimethylphenylamino)-7,9-dihydro-purin-8-one; [0320]
  • 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one; [0321]
  • 1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1H-imidazo[4,5-c]pyridine; [0322]
  • 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one; [0323]
  • 1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one; [0324]
  • 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one; [0325]
  • 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one; [0326]
  • 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine; [0327]
  • 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine; [0328]
  • 1(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]na phthyridine-3-carboxylic acid methyl ester; [0329]
  • 1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]na phthyridine-3-carboxylic acid isopropyl ester; [0330]
  • 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1 H-[1,6]naphthyridin-2-one; [0331]
  • 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine; [0332]
  • 1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene; [0333]
  • 1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene; [0334]
  • 1-(1-ethyl-propyl)-3,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-3-oxa-[1,6]-naphthyridin-2-one; [0335]
  • 1-(1-ethyl-propyl)-3,3,6-trimethyl-4-(2,4,6-trimethyl-phenoxy)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine; [0336]
  • 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine; [0337]
  • [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine; [0338]
  • (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine; [0339]
  • 7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine; [0340]
  • [2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl)-ethyl-propyl-amine; [0341]
  • [6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine; [0342]
  • (1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-amine; [0343]
  • [6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-methyl-amine; [0344]
  • 7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine; [0345]
  • 4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyr imidine; [0346]
  • (±)-2,5-dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine; [0347]
  • 2,5-dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine; [0348]
  • 2,5-dimethyl-4-( 1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine; [0349]
  • 4-sec-butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine; [0350]
  • 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one; [0351]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H- pyrido[2,3-b]pyrazin-2-one; [0352]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine; [0353]
  • 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0354]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0355]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,2-dihydro-3-oxa-1,8-diaza-naphthalen-4-one; [0356]
  • 8-(1-ethyl-propoxy)- 1,6-dimethyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0357]
  • (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine; [0358]
  • 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one; [0359]
  • 4-(butyl-ethyl-amino)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one; [0360]
  • 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one; [0361]
  • (butyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0362]
  • (propyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0363]
  • (diethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido [2,3-d]pyrimidin-4-yl]-amine; [0364]
  • (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0365]
  • (1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine; [0366]
  • 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one; [0367]
  • 4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one; [0368]
  • (butyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0369]
  • (propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0370]
  • (diethyl)-[2-methyl-8-( 2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine; [0371]
  • (1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro- pyrido[2,3-d]pyrimidin-4-yl]-amine; [0372]
  • (1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro- pyrido[2,3-d]pyrimidine; [0373]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-3,4-dihydro- 1H-pyrido [2,3-b]pyrazin-2-one; [0374]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0375]
  • 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinoline; [0376]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,4-dihydro-2H- 3-oxa-1,8-diaza-naphthalene; [0377]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl )-1,2-dihydro-3-oxa-1, 8-diaza-naphthalen-4-one; [0378]
  • 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0379]
  • (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinolin-4-yl]-amine; [0380]
  • 4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-chloro-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one; [0381]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one; [0382]
  • 8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0383]
  • 4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinoline; [0384]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,4-dihydro- 2H-3-oxa-1,8-diaza-naphthalene; [0385]
  • 5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl)-1,2-dihydro-3- oxa-1,8-diaza-naphthalen4-one; [0386]
  • 8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0387]
  • (1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinolin-4-yl]-amine; [0388]
  • 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one; [0389]
  • 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4- dihydro- 1H-pyrido[2,3-b]pyrazin-2-one; [0390]
  • 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one; [0391]
  • 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1 H-pyrido[2,3-b]pyrazin-2-one; [0392]
  • 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one; [0393]
  • 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido [2,3-b]pyrazin-2-one; [0394]
  • 8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl )-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0395]
  • 8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)- 1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0396]
  • 8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0397]
  • 8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine; [0398]
  • 8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0399]
  • 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine; [0400]
  • 4-(1-hydroxymethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0401]
  • 4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)- quinoline; [0402]
  • 4-(1-ethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0403]
  • 4-diethylamino-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0404]
  • 4-(ethyl-propyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0405]
  • 4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline; [0406]
  • 5-(1-hydroxymethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0407]
  • 5-(1-hydroxymethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl )-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0408]
  • 5-(1-ethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0409]
  • 5-diethylamino-5-methyl-1-(2,4,6-trimethyl-phenyl)- 1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0410]
  • 5-(ethyl-propyl-amino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0411]
  • 8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene; [0412]
  • 4-(2,4-dichlorophenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl)methyl)-N-pr opylamino]thiazole; [0413]
  • oxalate of 4-(2,4-dichlorophenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole; [0414]
  • oxalate of 4(2-methoxyphenyl)-5-2[-(6-methylisoquinol-5-yl)-N-propylamino]thiazole; [0415]
  • 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-methoxycarbonylmethylindol-5-yl)-N-p ropylamino]thiazole; [0416]
  • oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxy isoquinol-5-yl)-N-propylamino]thiazole; [0417]
  • oxalate of 4-2chloro4methoxyphenyl)-5-methyl-2-[N(6-chloroisoquinol-5-yl)-N- propylamino]thiazole; [0418]
  • oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole; [0419]
  • 4-(2-chloro-4-methoxyphenyl)-5methyl-2[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole; [0420]
  • oxalate of 4-(2-chloro-4-trifluoromethylphenyl)-5-methyl-2-[N-6-methoxyisoquinol-5-yl)-N-propylamino]thiazole; [0421]
  • chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-ethoxynaphth-1-yl)-N-propylamino]thiazole; [0422]
  • chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2[N-(2,3-dimethylnaphth-1-yl)-N-propylamino]thiazole; [0423]
  • chlorhydrate de 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-bromo-2-methoxynaphth-1-yl)-N-propylamino]thiazole; [0424]
  • chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,6-dimethylnaphth-1-yl)-N-propylamino]thiazole; [0425]
  • chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl)methyl)-N-propylamino]thiazole; [0426]
  • chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1 -(cyclopropyl)-1-(naphth-2-yl)methyl)-N-propylamino]thiazole; [0427]
  • 3-(2,4-dichlorophenyl)-5-methyl-7(N-propyl-N-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine; [0428]
  • 3-(2,4-dichlorophenyl)-5-methyl-7-(N-allyl-N-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine; [0429]
  • 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N,N-diallylamino) -pyrazolo[2,3-a]pyrimidine; [0430]
  • 2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-butyl-N-cyclopropanemethyl-amino)pyrazolo[2,3-alpyrimidine; [0431]
  • 2_methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-propyl-N-cyclopopanemethyl-amino) pyrazolo[2,3-a]pyrimidine; [0432]
  • 2-methyl-3-(4-chlorophenyl)-5-methyl-7-(N, N-dipropylamino)-pyrazolo[2,3-a) pyrimidine; [0433]
  • 3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine; [0434]
  • 3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]p yrimidine-7-amine; [0435]
  • 3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methyloxyethylamino)-pyrazolo (2,3-a)pyrimidine; [0436]
  • 7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine; [0437]
  • 7-(N-(3-cyanopropyl )-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine; [0438]
  • [3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine; [0439]
  • [2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-( 1-ethyl-propyl)-amine; [0440]
  • cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine; [0441]
  • cyclopropylmethyl-[3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine; [0442]
  • cyclopropylmethyl-[3-(2,4-di-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine; [0443]
  • [3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-di-propyl-amine; [0444]
  • [2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine; [0445]
  • [2,5-dimethyl-3-(2,4-dichloro-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine; and [0446]
  • 4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester. [0447]
  • Methods for making the CRF antagonists described above are disclosed in the above-listed patents and published patent applications incorporated by reference herein. [0448]
  • In an alternative embodiment, the present invention relates to a pharmaceutical composition for the treatment of a condition selected from the group consisting of: [0449]
  • a) abnormal circadian rhythm; and [0450]
  • b) depression. [0451]
  • The composition comprises an amount of a CRF antagonist effective to treat the condition in combination with a pharmaceutically acceptable carrier. Where the condition is depression, it is also treated with a second compound for treating depression, the second compound having an onset of action that is delayed with respect to that of the CRF antagonist. [0452]
  • In another aspect, the present invention relates to a method for treating or preventing a cardiovascular disease that involves administering a CRF antagonist, or a pharmaceutically acceptable salt, isomer, or prodrug thereof, in combination with a second, non-CRF antagonist compound for treating the disease. The second compound for treating the disease can be, for example, adenosine, alteplase, amiodarone, anagrelide, ardeparin, argatroban, atenolol, atorvastatin, benazepril, captopril, carvedilol, cerivastatin, clonidine, clopidrogrel, dalteparin, danaparoid, diltiazem, enalapril, fluvastatin, fosinopril, gemfibrozil, hydrochlorothiazide, irbesartan, lepirudin, lisinopril, lovastatin, oprelvekin, pravastatin, prazosin, quinapril, ramipril, saruplase, simvastatin, terazosin, valsartan, or verapamil. [0453]
  • In another aspect, the invention relates to treatment of migraine or non-migraine headache by administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition. For example, it is possible to administer a CRF antagonist with non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, acetaminophen, ibuprofen, with anti-emetics, with preparations containing ergotamine such as dihydroergotamine, or with agents that modulate serotonin receptors (including those that modulate the 5HT[0454] 1B, 5HT1D, 5HT1F and 5HT2B receptors) or that mimic the effects of serotonin. Particular agents include sumatriptan, naratriptan, zolmitriptan, rizatriptan, eletriptan, and almotriptan. Administration of these compounds is carried out using dosages and formulations that are well-known.
  • In another aspect, the invention relates to treatment of emesis using a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis. Examples of such non-CRF antagonist compounds for treating emesis include tachykinin antagonists, including Nk1 antagonists, (such as compounds described in WO 99/24423, EP 867182, EP 980324, and WO 99/24423) and 5HT[0455] 3 antagonists (such as metoclopramide, granisetron, dolasetron, ondansetron and tropisetron).
  • The emesis that is treated can be of any type, including emesis induced by pregnancy, vestibular disorder, post-operative sickness, gastrointestinal obstruction, reduced gastrointestinal motility, visceral pain, migraine, change in intercranial pressure, chemotherapy, radiation, toxins, and opioid analgesics. [0456]
  • The invention also encompasses combined pharmaceutical compositions containing the CRF antagonist, a non-CRF antagonist as defined above, and below, and a pharmaceutically acceptable carrier. Examples of such compositions include, without limitation: [0457]
  • 1) a composition for treating abnormal circadian rhythm that contains effective amounts of a combination of a CRF antagonist and a non-CRF antagonist compound useful for treating abnormal circadian rhythm; [0458]
  • 2) a composition for treating depression that contains effective amounts of a combination of a CRF antagonist and a second compound for treating depression that has a delayed effect; [0459]
  • 3) a composition for treating or preventing a cardiovascular disease that contains effective amounts of a CRF antagonist in combination with a second, non-CRF antagonist compound for treating the disease; [0460]
  • 4) a composition for treating migraine or non-migraine headache that contains effective amounts of a CRF antagonist in combination with a non-CRF antagonist compound that treats such condition; and [0461]
  • 5) a composition for treating emesis that contains a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis. [0462]
  • Combination treatments according to the invention can be administered as part of the same pharmaceutical composition, or the active agents can be administered separately as part of an appropriate dose regimen designed to obtain the benefits of the combination therapy. [0463]
  • Acid addition salts of the CRF antagonists and other agents employed in the invention can be prepared in a conventional manner by treating a solution or suspension of the corresponding free base with one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration or crystallization techniques can be employed to isolate the salts. Illustrative of suitable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric, sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, sulfonic acids such as methanesulfonic, benzene sulfonic, p- toluenesulfonic, and related acids. [0464]
  • The CRF antagonists and their pharmaceutically acceptable salts, and any second pharmaceutically active compounds, may be administered alone or in combination with pharmaceutically acceptable carriers, in either single or multiple doses. Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions, oils (e.g., peanut oil, sesame oil) and various organic solvents. The pharmaceutical compositions formed by combining the CRF antagonists and pharmaceutically acceptable carriers can be readily administered in a variety of dosage forms such as tablets, powders, lozenges, emulsions, oil soft gels, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrants such as starch, methylcellulose, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Preferred materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof. [0465]
  • For parenteral administration, solutions containing the CRF antagonist or a pharmaceutically acceptable salt thereof in sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solution may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. The sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. [0466]
  • The effective dosages for the CRF antagonists employed in the methods of this invention will depend on the intended route of administration and factors such as the age and weight of the patient, as generally known to a physician. The dosages will also depend on the particular condition to be treated and will generally range from about 0.1 to about 300 mg/kg body weight of the patient per day, with administration carried out in single or divided dosages. [0467]
  • Methods that may be used to determine the CRF antagonist activity of the compounds employed to practice the invention are described e.g., in Endocrinology, 116, 1653-1659 (1985) and Peptides, 10, 179-188 (1985). [0468]
  • Methods that can be used to determine the CRF binding protein inhibiting activity of compounds employed to practice the invention are described in Brain Research, (1997), 745(1,2), 248-256. The binding activities of the CRF antagonists employed generally range from about 0.5 nanomolar to about 32 micromolar. [0469]

Claims (10)

What is claimed is:
1. A method of treating a condition comprising administering a corticotropin releasing factor (CRF) antagonist in an amount effective to treat said condition, wherein said condition is selected from the group consisting of:
a) disorders that can be treated by altering circadian rhythm; and
b) depression, further wherein a second compound for treating depression is administered, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
2. The method of claim 1 wherein said condition is selected from the group consisting of time zone change syndrome, seasonal affective disorder, irregular sleep-wake pattern, delayed sleep phase syndrome, advanced sleep phase syndrome, non-24 hour sleep wake disorder, light-induced clock resetting, REM sleep disorder, hypersomnia, parasomnia, narcolepsy, nocturnal enuresis, restless legs syndrome, sleep apnea, dysthymia and abnormal circadian rhythm associated with chronic administration and withdrawal of antidepressant agents.
3. The method of claim 1 wherein said condition is depression, and wherein said second compound for treating depression is selected from the group consisting of selective serotonin reuptake inhibitors, tricyclic antidepressants, norepinephrine reuptake inhibitors, noradrenaline reuptake inhibitors, lithium, (α2-adrenoreceptor agonists, 5HT1A inhibitors, and monoamine oxidase type A inhibitors.
4. The method of claim 1 wherein said CRF antagonist is selected from the group consisting of 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine;
butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethyl-amino;
4-(butyl-ethylamino)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one;
4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;
N-butyl-N-ethyl-2,5-dimethyl-NN-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine;
[4-(1-ethyl-propoxy)-3,6-dimethyl-pyridin-2-yl]-(2,4,6-trimethylphenyl)-amine;
6-(ethyl-propyl-amino)-2,7-dimethyl-9-(2,4,6-trimethylphenyl)-7,9-dihydro-purin-8-one;
3-{(4-methyl-benzyl)-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-propan-1-ol;
diethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
2-butyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amino}-ethanol;
dibutyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-amine;
butyl-ethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
butyl-ethyl-[6-methyl-3-methylsulfonyl- 1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
butyl-cyclopropylmethyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
di-1-propyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
diallyl-[6-methyl-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
butyl-ethyl-[6-chloro-3-methylsulfanyl- 1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
butyl-ethyl-[6-methoxy-3-methylsulfanyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-amine;
propyl-ethyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin4-yl]-amine;
4-(1-ethyl-propyl)-6-methyl-3-methylsulfanyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidine;
n-butyl-ethyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
di-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
ethyl-n-propyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
diethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
n-butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
2-{N-n-butyl-N-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}-ethanol;
4-(1-ethyl-propyl)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine;
n-butyl-ethyl-[2,5-dimethyl-7-(2,4-dimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amine;
2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidyl-4-yl]-(1-ethyl-propyl)amine;
butyl-[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-ethylamine;
[3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4,b]pyridin-4-yl]-(1-methoxymethylpropyl)-amine;
4-(1-methoxymethylpropoxy)-3,6-dimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridine;
(1-ethylpropyl)-[3,5,6-trimethyl-1-(2,4,6-trimethylphenyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-amine;
4-(1-ethyl propoxy)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
4-(1-ethylpropoxy)-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-b]pyridine;
4-(1-ethylpropoxy)-2,5-dimethyl-7-(2,6-dimethyl-4-bromophenyl)-7H-pyrrolo[2,3-b]pyridine;
2,5,6-trimethyl-7-(1-propylbutyl)-4-(2,4,6-trimethylphenoxy)-7H-pyrrolo[2,3-d]pyrimidine;
1-(1-ethylpropyl)-6-methyl4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
9-(1-ethylpropyl)-2-methyl-6-(2,4,6-trimethylphenylamino)-7,9-dihydro-purin-8-one;
1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
1-(1-ethylpropyl)-6-methyl-4-(2,4,6-trimethylphenoxy)-1H-imidazo[4,5-c]pyridine;
1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenoxy)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
1-(1-ethylpropyl)-3,6-dimethyl-4-(2,4,6-trimethylphenylamino)-1,3-dihydro-imidazo[4,5-c]pyridin-2-one;
1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyrido[3,4-b]pyrazin-3-one;
1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-pyridol[3,4-b]pyrazin-3-one;
1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-pyrido[3,4-b]pyrazine;
1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine-3-carboxylic acid methyl ester;
1-(1-ethyl-propyl)-7-methyl-2-oxo-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine-3-carboxylic acid isopropyl ester;
1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-[1,6]naphthyridin-2-one;
1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,2,3,4-tetrahydro-[1,6]naphthyridine;
1-(1-ethyl-propyl)-7-methyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
1-(1-ethyl-propyl)-4,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-1,4-dihydro-2H-3-oxa-1,6-diaza-naphthalene;
1-(1-ethyl-propyl)-3,7-dimethyl-5-(2,4,6-trimethyl-phenoxy)-3,4-dihydro-1H-3-oxa-[1,6]-naphthyridin-2-one;
1-(1-ethyl-propyl)-3,3,6-trimethyl-4-(2,4,6-trimethyl-phenoxy)-2,3-dihydro-1H-pyrrolo[3,2-c]pyridine;
7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;
(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-amine;
7-(1-ethyl-propoxy)-2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidine;
[2,5-dimethyl-3-(2,4,6-trimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-ethyl-propyl-amine;
[6-bromo-5-bromomethyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-amine;
(1-ethyl-propyl)-[5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin yl]-amine;
[6-bromo-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridin-7-yl]-(1-ethyl-propyl)-methyl-amine;
7-(1-ethyl-propoxy)-5-methyl-3-(2,4,6-trimethyl-phenyl)-3H-[1,2,3]triazolo[4,5-b]pyridine;
4-(1-ethyl-propoxy)-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyr imidine;
(±)-2,5-dimethyl-4-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
2,5-dimethyl-4-(S)-(tetrahydro-furan-3-yloxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo-[3,2-d]pyrimidine;
2,5-dimethyl-4-(1-propyl-butoxy)-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
4-sec-butylsulfanyl-2,5-dimethyl-7-(2,4,6-trimethyl-phenyl)-5H-pyrrolo[3,2-d]pyrimidine;
4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one;
8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-l H- pyrido[2,3-b]pyrazin-2-one;
8-(1-ethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine;
4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(1-ethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,2-dihydro-3-oxa-1,8-diaza-naphthalen-4-one;
8-(1-ethyl-propoxy)- 1,6-dimethyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
(1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-quinolin-4-yl]-amine;
4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
4-(butyl-ethyl-amino)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
(butyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(propyl-ethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(diethyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl )-5,6,7,8-tetrahydro-pyrido [2,3-d]pyrimidin-4-yl]-amine;
(1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl )-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine;
4-(butyl-ethyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl )-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
4-(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-5,8-dihydro-6H-pyrido [2,3-d]pyrimidin-7-one;
(butyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(propyl-ethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimid in-4-yl]-amine;
(diethyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(1-ethyl-propyl)-[2-methyl-8-(2,4,6-trimethyl-phenyl)-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl]-amine;
(1-ethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl )-5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidine;
8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-3,4-dihydro- 1H-pyrido [2,3-b]pyrazin-2-one;
8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-bromo-phenyl)-quinoline;
5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-bromo-phenyl)-1,2-dihydro-3-oxa-1, 8-diaza-naphthalen-4-one;
8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-bromo-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
(1-ethyl-propyl)-[2-methyl-8-(2,6-dimethyl-4-bromo-phenyl )-quinolin-4-yl]-amine;
4-(butyl-ethyl-amino)-2,6-dimethyl-8-(2,6-dimethyl-4-chloro-phenyl)-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one;
8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
8-(1-ethyl-propoxy)-6-methyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
4-(1-ethyl-propoxy)-2-methyl-8-(2,6-dimethyl-4-chloro-phenyl )-quinoline;
5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl )-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(1-ethyl-propoxy)-7-methyl-1-(2,6-dimethyl-4-chloro-phenyl )-1,2-dihydro-3-oxa-1,8-diaza-naphthalen-4-one;
8-(1-ethyl-propoxy)-1,6-dimethyl-4-(2,6-dimethyl-4-chloro-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
(1-ethyl-propyl )-[2-methyl-8-(2,6-dimethyl-4-chloro-phenyl)-quinolin-4-yl]-amine;
8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro- 1H-pyrido[2,3-b]pyrazin-2-one;
8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4- dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl )-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one;
8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-one
8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-3,4-dihydro-1H-pyrido [2,3-b]pyrazin-2-one;
8-(1-hydroxymethyl-propoxy)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
8-(1-hydroxymethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
8-(1-ethyl-propylamino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
8-diethylamino-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido [2,3-b]pyrazine;
8-(ethyl-propyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
8-(butyl-ethyl-amino)-6-methyl4-(2,4,6-trimethyl-phenyl)-1,2,3,4-tetrahydro-pyrido[2,3-b]pyrazine;
4-(1-hydroxymethyl-propoxy)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
4-(1-hydroxymethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
4-(1-ethyl-propylamino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
4-diethylamino-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
4-(ethyl-propyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
4-(ethyl-propyl-amino)-2-methyl-8-(2,4,6-trimethyl-phenyl)-quinoline;
5-(1-hydroxymethyl-propoxy)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(1-hydroxymethyl-propylamino)-7-methyl- 1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(1-ethyl-propylamino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-diethylamino-5-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
5-(ethyl-propyl-amino)-7-methyl-1-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
8-(butyl-ethyl-amino)-6-methyl-4-(2,4,6-trimethyl-phenyl)-1,4-dihydro-2H-3-oxa-1,8-diaza-naphthalene;
4-(2,4-dichlorophenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl)methyl)-N-pr opylamino]thiazole;
oxalate of 4-(2,4-dichlorophenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
oxalate of4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methylisoquinol-5-y)-N-propylamino]thiazole;
4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-methoxycarbonylmethylindol-5-yl)-N-p ropylamino]thiazole;
oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxy isoquinol-5-yl)-N-propylamino]thiazole;
oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-chloroisoquinol-5-yl)-N-propylamino]thiazole;
oxalate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
4(2-chloro-4-methoxyphenyl)-5-methyl-2[N-1methoxynaphth-2-yl)-N-propylamino]thiazole
oxalate of 4-(2-chloro-4-trifluoromethylphenyl)-5-methyl-2-[N-6-methoxyisoquinol-5-yl)-N-propylamino]thiazole;
chlorahydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2-ethoxynaphth-1-yl)-N-propylamino]thiazole; chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2[N-(2,3-dimethylnaphth-1-yl)-N-propylamino]thiazole;
chlorhydrate de 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(6-bromo-2-methoxynaphth-1-yl)-N-propylamino]thiazole;
chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(2,6-dimethylnaphth-1-yl)-N-propylamino]thiazole;
chlorhydrate of 4-(2-chloro-4-methoxyphenyl)-5-methyl-2-[N-(1-(methoxymethyl)-1-(naphth-2-yl)methyl)-N-propylamino]thiazole;
chlorhydrate of 4-(2-chloro4-methoxyphenyl)-5-methyl-2-[N-(1 -(cyclopropyl)-1 -(naphth-2-yl )methyl)-N-propylamino]thiazole;
3-(2,4-dichlorophenyl)-5-methyl-7(N-propyl-N-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine;
3-(2,4-dichlorophenyl)-5-methyl-7-(N-allyl-N-cyclopropanemethylamino)-pyrazolo[2,3-a]pyrimidine;
2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N,N-diallylamino)-pyrazolo[2,3-a]pyrimidine;
2-methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-butyl-N-cyclopropanemethyl-amino)pyrazolo[2,3-alpyrimidine; 2_methylthio-3-(2,4-dichlorophenyl)-5-methyl-7-(N-propyl-N-cyclopopanemethyl-amino) pyrazolo[2,3-a]pyrimidine;
2-methyl-3-(4-chlorophenyl)-5-methyl-7-(N,N-dipropylamino)-pyrazolo[2,3-a) pyrimidine;
3-[6-(dimethylamino)-3-pyridinyl-2,5-dimethyl-N,N-dipropylpyrazolo[2,3-a]pyrimidin-7-amine;
3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-N,N-dipropyl-pyrazolo[2,3-a]pyrimidine-7-amine;
3-(2,4-dimethoxyphenyl)-2,5-dimethyl-7-(N-propyl-N-methyloxyethylamino)-pyrazolo (2,3-a)pyrimidine;
7-(N-diethylamino)-2,5-dimethyl-3-(2-methyl-4-methoxyphenyl-[1,5-a]-pyrazolopyrimidine;
7-(N-(3-cyanopropyl)-N-propylamino-2,5,dimethyl-3-(2,4-dimethylphenyl)-[1,5-a]-pyrazolopyrimidine;
[3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl]-(1-ethyl-propyl)-amine;
[2-(4-chloro-2,6-dimethyl-phenoxy)-3,6-dimethyl-pyridin-4-yl]-(1-ethyl-propyl)-amine;
cyclopropylmethyl-[3-(2,4-dimethyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-alpyrimidin-7-yl]-propyl-amine;
cyclopropylmethyl-[3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
cyclopropylmethyl-[3-(2,4-di-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-propyl-amine;
[3-(2-methyl-4-chloro-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-di-propyl-amine;
[2,5-dimethyl-3-(2,4-dimethyl-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine;
[2,5-dimethyl-3-(2,4-dichloro-phenyl)-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine; and
4-(1-Ethyl-propylamino)-6-methyl-2-(2,4,6-trimethyl-phenoxy)-nicotinic acid methyl ester.
5. A pharmaceutical composition for the treatment of a condition selected from the group consisting of:
a) abnormal circadian rhythm; and
b) depression;
comprising an amount of a CRF antagonist effective to treat said condition in combination with a pharmaceutically acceptable carrier,
wherein where said condition is depression, said depression is treated with a second compound for treating depression, said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
6. The pharmaceutical composition of claim 5 for treatment of depression comprising an amount of a CRF antagonist effective to treat said depression, and said second compound for treating depression having an onset of action that is delayed with respect to that of said CRF antagonist.
7. A method for treating or preventing a cardiovascular disease comprising administering a CRF antagonist, or a pharmaceutically acceptable salt, isomer, or prodrug thereof, in combination with a non-CRF antagonist compound for treating said disease.
8. A method for treating migraine or non-migraine headache comprising administration of a CRF antagonist in combination with a non-CRF antagonist compound that treats said headache.
9. The method of claim 8 wherein said non-CRF antagonist compound is selected from the group consisting of non-steroidal anti-inflammatory drugs, anti-emetics, ergotamine, and agents that modulate serotonin receptors or mimic the effects of serotonin.
10. A method for treating emesis comprising administration of a CRF antagonist in combination with a non-CRF antagonist compound for treating emesis.
US10/161,816 1999-08-27 2002-06-04 Use of CRF antagonists and related compositions Abandoned US20020156089A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/161,816 US20020156089A1 (en) 1999-08-27 2002-06-04 Use of CRF antagonists and related compositions
US10/676,201 US20040082597A1 (en) 1999-08-27 2003-10-01 Use of CRF antagonists and related compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15118399P 1999-08-27 1999-08-27
US09/587,007 US6432989B1 (en) 1999-08-27 2000-06-05 Use of CRF antagonists to treat circadian rhythm disorders
US10/161,816 US20020156089A1 (en) 1999-08-27 2002-06-04 Use of CRF antagonists and related compositions

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/587,007 Division US6432989B1 (en) 1999-08-27 2000-06-05 Use of CRF antagonists to treat circadian rhythm disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/676,201 Division US20040082597A1 (en) 1999-08-27 2003-10-01 Use of CRF antagonists and related compositions

Publications (1)

Publication Number Publication Date
US20020156089A1 true US20020156089A1 (en) 2002-10-24

Family

ID=22537665

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/587,007 Expired - Fee Related US6432989B1 (en) 1999-08-27 2000-06-05 Use of CRF antagonists to treat circadian rhythm disorders
US10/161,816 Abandoned US20020156089A1 (en) 1999-08-27 2002-06-04 Use of CRF antagonists and related compositions
US10/676,201 Abandoned US20040082597A1 (en) 1999-08-27 2003-10-01 Use of CRF antagonists and related compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/587,007 Expired - Fee Related US6432989B1 (en) 1999-08-27 2000-06-05 Use of CRF antagonists to treat circadian rhythm disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/676,201 Abandoned US20040082597A1 (en) 1999-08-27 2003-10-01 Use of CRF antagonists and related compositions

Country Status (12)

Country Link
US (3) US6432989B1 (en)
EP (1) EP1082960A3 (en)
JP (1) JP2001097889A (en)
KR (1) KR20010050223A (en)
AU (1) AU776077B2 (en)
CA (1) CA2316662A1 (en)
CO (1) CO5190684A1 (en)
HU (1) HUP0003386A3 (en)
IL (1) IL137935A0 (en)
NZ (1) NZ506562A (en)
PE (1) PE20010528A1 (en)
ZA (1) ZA200004362B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CN1379678A (en) 1999-10-01 2002-11-13 强生消费者公司 Method for calming human beings using personal care compositions
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
CN1649848A (en) * 2001-04-30 2005-08-03 葛兰素集团有限公司 Fused pyrimidines derivatives as antagonists of the corticotropin releasing factor (CRF)
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
GB2411478A (en) 2002-01-29 2005-08-31 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
GB0203045D0 (en) * 2002-02-08 2002-03-27 Johnson & Johnson Consumer Method of afefecting sleep and sleep-related behaviours
AU2003233519A1 (en) 2002-05-29 2003-12-19 3M Innovative Properties Company Process for imidazo(4,5-c)pyridin-4-amines
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
WO2003103643A1 (en) 2002-06-10 2003-12-18 Philippe Kriwin Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor
CA2523261C (en) * 2003-05-05 2009-07-07 F. Hoffmann-La Roche Ag Fused pyrimidine derivatives with crf activity
CA2534785A1 (en) 2003-08-12 2005-02-17 Robin Douglas Clark Tetrahydroquinazoline derivatives as cfr antagonists
CA2535249A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
JP2007502288A (en) 2003-08-12 2007-02-08 スリーエム イノベイティブ プロパティズ カンパニー Oxime-substituted imidazo-containing compounds
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
BRPI0414856A (en) 2003-10-03 2006-11-21 3M Innovative Properties Co alkoxy-substituted imidazoquinolines
JP2007509838A (en) * 2003-10-29 2007-04-19 メンドレウィクツ，ジュリエン Oral antidepressant preparation comprising acetylsalicylic acid that promotes onset of action
CA2545774A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
WO2005048945A2 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
US8691837B2 (en) 2003-11-25 2014-04-08 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007512350A (en) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Carvedilol composition treatment and delivery methods
JP5072364B2 (en) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド Carvedilol free base, carvedilol salt, anhydrous form or solvate thereof, corresponding pharmaceutical composition, controlled release formulation and treatment or delivery method
US7402672B2 (en) * 2003-12-11 2008-07-22 Aventis Pharmaceuticals Inc. Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon
JP2007515474A (en) * 2003-12-22 2007-06-14 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド CRF receptor antagonists and methods related thereto
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
US8735421B2 (en) 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
JP2007522200A (en) * 2004-02-13 2007-08-09 ファイザー・プロダクツ・インク Therapeutic combination of atypical antipsychotics and corticotropin releasing factor antagonists
WO2005079868A2 (en) * 2004-02-13 2005-09-01 Sb Pharmco Puerto Rico Inc Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2594674C (en) 2004-12-30 2016-05-17 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
WO2006074003A2 (en) 2004-12-30 2006-07-13 3M Innovative Properties Company CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US8987232B2 (en) 2008-09-04 2015-03-24 The University Of Tokyo Agent for ameliorating brain hypofunction
EP2536720A1 (en) 2010-02-18 2012-12-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Triazolo [4, 5 - b]pyridin derivatives
CN108025008A (en) * 2015-06-22 2018-05-11 安比拉神经疗法公司 The composition and method of obstacle, habituation and mental disease are used for therapeutic substance
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
AU2018230521B2 (en) 2017-03-10 2022-02-03 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
CN109528670B (en) * 2018-12-28 2021-05-07 正大制药（青岛）有限公司 Frovatriptan succinate tablet and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880135A (en) * 1995-06-21 1999-03-09 Sanofi Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
FR2692893B1 (en) 1992-06-24 1994-09-02 Sanofi Elf Branched alkylamino thiazole derivatives, processes for their preparation and pharmaceutical compositions containing them.
JP2895961B2 (en) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Pyrrolopyrimidines as CRF antagonists
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
CA2192208C (en) 1994-06-06 2002-09-10 Pfizer Limited Substituted pyrazoles
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US5646152A (en) * 1994-06-15 1997-07-08 Pfizer Inc. Methods of administering CRF antagonists
MX9606504A (en) 1994-06-16 1997-03-29 Pfizer Pyrazolo and pyrrolopyridines.
KR100256707B1 (en) 1995-05-12 2000-05-15 해피 페너 Novel deazapurine derivatives; a new class of crf1 specific ligands
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
US5955613A (en) 1995-10-13 1999-09-21 Neurogen Corporation Certain pyrrolopyridine derivatives; novel CRF1 specific ligands
EP0863882B1 (en) 1995-10-17 2002-02-06 Janssen Pharmaceutica N.V. Amino substituted pyrimidines and triazines
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
ES2167710T3 (en) 1996-02-07 2002-05-16 Janssen Pharmaceutica Nv THIOPHENOPIRIMIDINS.
EA000803B1 (en) 1996-02-07 2000-04-24 Жансен Фармасетика Н.В. Pyrazolopyrimidines as crf receptor antagonists
JP2000507552A (en) 1996-03-26 2000-06-20 デュポン ファーマシューティカルズ カンパニー Aryloxy and arylthio fused pyridines, aryloxy and arylthio fused pyrimidines and derivatives thereof
US6326368B1 (en) 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
ZA973884B (en) 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
ATE375344T1 (en) 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co AZOLOTRIAZINES AND PYRIMIDINES
CZ292806B6 (en) 1996-08-06 2003-12-17 Pfizer Inc. Pyrido- or pyrimido-6,6- or -6,7-bicyclic derivatives and pharmaceutical compositions based thereon
US5861398A (en) 1996-08-26 1999-01-19 Alanex Corporation Benzoperimidine-carboxylic acids and derivatives thereof
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
TR199900389T2 (en) 1996-08-28 2000-06-21 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives.
US6159980A (en) 1996-09-16 2000-12-12 Dupont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (en) 1996-10-08 1998-12-31 Sanofi Sa AMINOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5760225A (en) 1996-11-15 1998-06-02 Neurogen Corporation Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands
CA2275686C (en) 1996-12-18 2006-10-17 Neurogen Corporation Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
WO1998029397A1 (en) 1996-12-27 1998-07-09 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
US5723608A (en) 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
CA2281525A1 (en) 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists
PT976745E (en) 1997-03-26 2003-12-31 Taisho Pharmaceutical Co Ltd DERIVED FROM 4-TETRAHYDROPYRIDYLPYRIMIDINE
AU751710B2 (en) 1997-04-22 2002-08-22 Neurocrine Biosciences Inc. CRF antagonistic thiophenopyridines
US6482836B1 (en) 1997-04-22 2002-11-19 Charles Huang CRF antagonistic quino- and quinazolines
TW453999B (en) 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
EP0994860A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists
CA2294117A1 (en) 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
WO1999010350A1 (en) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
NL1010018C2 (en) 1997-09-09 1999-03-10 Duphar Int Res Quinoline and quinazoline derivatives with corticotropin releasing factor (CRF) antagonistic effect.
DK1049699T3 (en) 1998-01-28 2004-07-05 Bristol Myers Squibb Pharma Co Pyrazolotriazines as CRF antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880135A (en) * 1995-06-21 1999-03-09 Sanofi Substituted 4-phenylaminothiazoles, their process of preparation and the pharmaceutical compositions containing them
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8414920B2 (en) 2004-06-04 2013-04-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia

Also Published As

Publication number Publication date
AU776077B2 (en) 2004-08-26
JP2001097889A (en) 2001-04-10
EP1082960A2 (en) 2001-03-14
HUP0003386A2 (en) 2001-07-30
EP1082960A3 (en) 2002-03-20
IL137935A0 (en) 2001-10-31
US6432989B1 (en) 2002-08-13
AU5364400A (en) 2001-03-01
CA2316662A1 (en) 2001-02-27
KR20010050223A (en) 2001-06-15
ZA200004362B (en) 2002-02-25
CO5190684A1 (en) 2002-08-29
HUP0003386A3 (en) 2003-08-28
NZ506562A (en) 2002-09-27
US20040082597A1 (en) 2004-04-29
PE20010528A1 (en) 2001-05-10
HU0003386D0 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
US6432989B1 (en) Use of CRF antagonists to treat circadian rhythm disorders
AU776724B2 (en) Use of corticotropin releasing factor antagonists and related compositions
US20010041673A1 (en) Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
AU761694B2 (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
JP2000001434A (en) Pharmaceutical composition containing corticotropin releasing factor antagonist
US6403599B1 (en) Corticotropin releasing factor antagonists
US20050209250A1 (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
CA2602294C (en) Heterobicylic inhibitors of hvc
KR101258426B1 (en) Combinations for the treatment of diseases involving cell proliferation
JP6695353B2 (en) Formylated N-heterocyclic derivatives as FGFR4 inhibitors
RU2000110738A (en) BICYCLIC KINASE INHIBITORS
TW201316991A (en) Combination of MEK inhibitors and selective inhibitors of Aurora A kinase
RU2019108259A (en) COMBINATION THERAPY FOR HEPATOCELLULAR CARCINOMA
EP1449532A1 (en) Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist
MXPA06009271A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP2007517854A (en) Combination of CRF antagonist and 5-HT1B receptor antagonist

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION